



**SAPIENZA**  
UNIVERSITÀ DI ROMA

**Dottorato di Ricerca in**  
**Fisiopatologia e Imaging Cardio-Toraco-Vascolare**  
**XXXII Ciclo**

*Coordinatore Prof. Federico Venuta*

TESI DI DOTTORATO

**CLINICAL IMPACT OF RIGHT VENTRICULAR DIASTOLIC  
PATTERNS BY SPECKLE TRACKING ECHOCARDIOGRAPHY  
IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION**

TUTOR

Chiar.mo Prof. Carmine Dario Vizza

DOTTORANDA

Dr.ssa Beatrice Pezzuto

AA 2018/2019

## INDEX

<u>INTRODUCTION</u>	<u>3</u>
<u>1. PULMONARY HYPERTENSION</u>	<u>5</u>
1.1 Physiology of pulmonary circulation	5
1.2 Pulmonary hypertension: general overview	6
1.3 Pulmonary arterial hypertension	8
1.3.1 Epidemiology and pathogenesis	8
<u>2. THE RIGHT VENTRICLE</u>	<u>13</u>
2.1 Anatomy, physiology and pathophysiology	13
2.2 Impact of pulmonary hypertension on the right ventricle and right heart failure	17
2.3 RV systolic function and RV-arterial coupling	17
2.4 Right ventricular diastolic function	21
2.5 Ventricular interaction	23
<u>3. ROLE OF DOPPLER ECHOCARDIOGRAPHY IN THE STUDY OF PAH</u>	<u>25</u>
3.1 Non-invasive assessment of the RV: standard Doppler echocardiography	26
3.2 Non-invasive estimation of pulmonary arterial pressure	28
3.3 Prognostic value of right ventricular dysfunction	30
<u>4. DEFORMATION AND DYSSYNCHRONY OF THE RIGHT VENTRICLE</u>	<u>31</u>
4.1 The concept of strain	31
4.2 Speckle tracking echocardiography	31

4.3	Systolic deformation and dyssynchrony of the right ventricle	33
4.4	Right ventricular strain and diastolic function	36
<b>5. EXPERIMENTAL SECTION</b>		<b>37</b>
<hr/>		
5.1	Aim of the study	37
5.2	Methods	38
5.2.1	Population and study protocol	38
5.2.2	Right heart catheterization	38
5.2.3	Standard echocardiography	39
5.2.4	2D Speckle Tracking Ecocardiography	39
5.2.5	Statistical analysis	40
5.3	Results	42
5.3.1	2D diastolic patterns in PAH	42
5.3.2	2D diastolic patterns and RV adaptation to afterload	44
5.3.3	2D diastolic patterns and clinical worsening	47
5.4	Discussion	50
5.5	Study limitations	52
5.6	Conclusions	53
<b>REFERENCES</b>		<b>54</b>
<hr/>		

## INTRODUCTION

Pulmonary arterial hypertension (PAH) is a rare disease characterized by an increase in pulmonary vascular resistance (PVR) due to remodeling, fibrosis and thrombosis in situ of pulmonary arterioles, with consequent pressure overload and right heart failure. PAH main clinical manifestations are reduced exercise capacity and fluid retention; in the absence of treatment, the disease inevitably evolves to death.<sup>(1)</sup>

The pathophysiological model of the disease is an afterload mismatch, thus right ventricle (RV) ability to adapt to increased afterload (RV ventricular-arterial coupling) is the main determinant of symptoms, clinical status and prognosis of affected patients.<sup>(2)</sup> It is therefore evident that RV morphological and functional status represents a fundamental target of clinical, prognostic and therapeutic evaluation in PAH patients.

Although it is well known that RV systolic adaptation to increased afterload is of main clinical importance, also the diastolic function can account for many pathophysiological and clinical aspects of the disease.

The study of RV diastolic function has been challenging for long time. The gold standard load-independent measurement by pressure-volume (PV) analysis is rather risky in PAH patients, requiring temporal preload reduction by vena cava occlusion,<sup>(3)</sup> while both right heart catheterization and noninvasive imaging techniques (echocardiography, magnetic resonance imaging - MRI) provide indirect surrogates of diastolic function that have shown to have prognostic value in many studies, but are nevertheless highly dependent on the confounding effects of increased preload and afterload, so they cannot provide insight into the intrinsic alteration of RV myocardium independently of load condition, and are therefore not always reliable in PAH patients.<sup>(3,4)</sup>

The single-beat method to determine load-independent RV diastolic stiffness avoiding vena cava occlusion has been validated in the last years,<sup>(5)</sup> allowing to find clinically significant diastolic dysfunction in PAH patients, characterized by increased diastolic

stiffness, fibrosis and sarcomeric alterations.<sup>(5, 6, 7)</sup> However, it requires complex mathematical modeling and MR imaging, which are not easy to use in routine clinical practice.

The assessment of diastolic stiffness by standard echocardiography-derived left ventricular (LV) wall strain measurements has shown in the last years promising results in patients with LV diastolic dysfunction,<sup>(8,9)</sup> suggesting strain analysis as a potential tool for noninvasive evaluation of real diastolic function. A recent study on PAH patients<sup>(10)</sup> showed that in chronic RV overload, cardiac MR-determined RV strain is associated with RV-arterial uncoupling and RV end-diastolic stiffness, suggesting it as a promising noninvasive alternative to current invasive methods for assessment of both systolic and diastolic RV function. However, it still requires MRI, which is not possible to use in all patients, not bedside and in patient' strict follow-up.

Moreover, it is not yet well known whether RV diastolic function assessment in PAH is of added prognostic value beside traditional clinical, hemodynamic and RV systolic functional parameters.

Two-dimensional (2D) Speckle Tracking Echocardiography (STE), an ultrasonographic imaging method that allows to analyze displacement and deformation of predefined myocardial regions, overcoming the limits of M-mode and tissue Doppler imaging, as well as MRI temporal resolution limits, has gained importance for RV systolic function evaluation in the last years, allowing the evaluation of RV strain and dyssynchrony.<sup>(11,12,13)</sup> To date, the STE study of RV diastolic function has been neglected.

The aim of the work presented in this thesis is therefore to describe strain-derived RV diastolic patterns by speckle tracking echocardiography and their clinical impact in a large population of idiopathic pulmonary arterial hypertension (IPAH) patients, and to verify if the evaluation of these patterns provides additive prognostic information to traditional clinical, hemodynamic and RV systolic indices analysis.

# 1 - PULMONARY HYPERTENSION

## 1.1 PHYSIOLOGY OF PULMONARY CIRCULATION

The main function of the pulmonary circulation is to allow an adequate perfusion of the alveolar units for the gas exchange, and subsequent transport of oxygen to all the tissues of the organism. At this aim, the pulmonary circulation is conceived as a high-flow/low resistance system coupled with a thin-walled flow-generating chamber, the right ventricle, which is relatively unable to tolerate afterload increases.

The normal pulmonary artery pressure has a systolic peak of 18-25 mmHg, a telediastolic value of 6-10 mmHg and an average value between 12 and 16 mmHg. The normal mean pulmonary venous pressure is 6-10 mmHg, therefore the flow pressure through the pulmonary vascular bed fluctuates between 2 and 10 mmHg.<sup>(14)</sup> This small pressure gradient is sufficient to ensure the passage of the entire cardiac output through the pulmonary circulation; this is made possible by the low resistance to flow offered by the pulmonary vessels themselves, equal to about one fifth of the systemic circulation. In physiological conditions, increases in blood flow do not significantly change pulmonary arterial pressure: this indicates that pulmonary vascular resistance can further be reduced in response to increases in cardiac output, first due to the recruitment of new vessels, subsequently to distension of pulmonary vessels.

These hemodynamic characteristics are due to the anatomical structure of the pulmonary circulation. The wall of the large-sized pulmonary arteries is made up of smooth muscle cells that are inserted directly on short elastic fibers, therefore these arteries are particularly suitable for stretching when stressed by an increase in transmural tension. The small muscular arteries are instead responsible for the local regulation of the vascular tone: the terminal branches of these vessels have a larger caliber and have a thinner wall than the corresponding systemic arteries. Normally the contribution of pulmonary capillaries to

vascular resistance is minimal, but, due to the narrow anatomical relationships between capillary and alveolus, an increase in alveolar volume may cause a reduction in the capillary diameter.<sup>(15)</sup>

Endothelial cells play a major role in maintaining these anatomical and functional characteristics. Indeed, they are an important source of vasoconstrictor factors (endothelin 1-ET-1 and thromboxane A2) and vasodilators (nitric oxide-NO and prostacyclin), which also act as mitotic and antimitotic agents, respectively. The physiological characteristics of the pulmonary circulation (low resistance, high flow) are due to the prevailing of vasodilating/antimitogenic factors over vasoconstrictors/mitogens.<sup>(14,15,16)</sup>

Regardless of the responsible mechanisms, maintaining a low resistance in the pulmonary circulation is necessary to prevent overloading of the right ventricle, whose anatomical and functional characteristics allow a good adaptation to volume, but not to pressure overload; in this last situation it rapidly goes towards a contractile insufficiency.<sup>(17)</sup>

## **1.2 PULMONARY HYPERTENSION: GENERAL OVERVIEW**

According to current guidelines, pulmonary hypertension (PH) is defined as a hemodynamic and pathophysiological condition characterized by a mean pulmonary arterial pressure (mPAP) value  $\geq 25$  mmHg at rest, measured by right heart catheterization. It may occur during several diseases of cardiorespiratory origin, but it can also be related to immune, viral or iatrogenic diseases (appetite suppressant drugs).<sup>(18)</sup>

The prognosis is still related above all to the ability of the cardiovascular system to respond to the increased pressure in pulmonary circulation, and in particular to the ability of the right ventricle to maintain functional integrity in the face of increased afterload.<sup>(19)</sup>

In 1998, the World Health Organization proposed a new classification of pulmonary hypertension, based on the different pathophysiological mechanisms involving the pulmonary vascular district in the various forms of the pathology.<sup>(20)</sup> This classification was

subsequently updated in Venice in 2003, in Dana Point in 2008 and in Nice in 2013; a last update has been finally proposed in Nice in 2018, with mild modification.<sup>(21)</sup>

The current classification groups the pathologies associated to PH considering the pathogenetic and histopathological analogies of the various diseases. The importance of this nosographic classification consists in recognizing a common pathogenetic and prognostic pathway and the same therapeutic approach in the pathologies included in the same group. According the current guidelines (Table 1),<sup>(18)</sup> referring to Nice 2013, the different types of pulmonary hypertension can be divided into five groups based on the pathogenic mechanisms:

- Pulmonary arterial hypertension, which includes idiopathic and hereditary forms, and those associated with other pathological conditions, such as connective tissue diseases, portal hypertension, HIV infection or congenital heart disease with pulmonary hyperflow, assumption of appetite suppressant drugs, schistosomiasis; two subgroups have been added to this group: 1 'for pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis, and 1' 'for persistent pulmonary hypertension of the newborn.
- Venous pulmonary hypertension, in which the increase in pulmonary pressure has as primum movens an increase in pulmonary vein pressure or in the left atrium. This group includes pulmonary hypertension associated to pathologies of the left heart and pulmonary hypertension associated with extrinsic compressions of the pulmonary veins.
- Pulmonary hypertension associated with lung diseases and/or hypoxia.
- Pulmonary hypertension secondary to thromboembolism or other obstruction of the pulmonary arteries.
- Pulmonary hypertension secondary to rare diseases that directly involve the pulmonary circulation with mechanisms that are not yet clear or multifactorial (hematological diseases such as chronic hemolytic anemia, systemic diseases such as sarcoidosis or neurofibromatosis, metabolic diseases such as Gaucher disease, etc.).



From a purely hemodynamic point of view, moreover, PH can be distinguished in precapillary forms, defined by a pulmonary capillary wedge pressure (WP)  $\leq 15$  mmHg (Groups 1, 3 and 4), and post-capillary forms, with WP  $> 15$  mmHg (Group 2).<sup>(18)</sup>

### **1.3 PULMONARY ARTERIAL HYPERTENSION**

Pulmonary arterial hypertension (PAH, Group 1 of classification) is defined as a clinical condition characterized by the presence of pre-capillary pulmonary hypertension, with pulmonary vascular resistance  $> 3$  WU, in the absence of other known causes of precapillary pulmonary hypertension, like pneumopathies or chronic thromboembolism. PAH includes different forms (idiopathic or associated with other pathological conditions), presenting a similar clinical picture and virtually identical pathological changes of pulmonary arterial microcirculation, and represents the most severe form of pre-capillary pulmonary hypertension together with PH secondary to chronic thromboembolism (CTEPH, chronic thromboembolic pulmonary hypertension).<sup>(18)</sup>


#### **1.3.1 Epidemiology and pathogenesis**

Idiopathic pulmonary arterial hypertension (IPAH) is a rare disease, having an incidence of about 2 cases per million inhabitants, and is the most severe form of pulmonary arterial hypertension.

A familiarity can be found in about 7-10% of cases; the most frequently involved alterations concern genes encoding receptors for the TGF- $\beta$  family (BMPR2, whose heterozygous mutation has been identified in 75% of familial cases and up to 25% of apparently sporadic cases,<sup>(22,23)</sup> ALK-1,<sup>(24)</sup> endoglin, BMPR1B and SMAD9,<sup>(22)</sup> while rare mutations have been found in genes encoding proteins such as caveolin 1 and potassium channels (KCNK3).<sup>(22,25)</sup>

The average age of onset of the disease is around 30-40 years, but it can also occur in elderly and pediatric subjects; female is most affected sex.


In the "associated" forms, pulmonary arterial hypertension presents different prevalence depending on the underlying disease. It is found in about 5% of patients with CREST variant of scleroderma, while in HIV and portal hypertension PAH prevalence is around 0.5-1%. The prevalence of the disease is lower in patients who have used appetite suppressant drugs, with 1 case per 10000-17000 subjects, depending on the duration of exposure to the substance (aminorex, fenfluramine, dexfenfluramine).<sup>(18)</sup> These epidemiological observations allow us to identify a series of very different "associated" factors, which reflect an increased risk of developing pulmonary arterial hypertension, but which are not certain etiological factors. We are probably faced with a complex multifactorial syndrome (Figure 1), in which there is a genetic predisposition that confers a particular pulmonary vascular reactivity to several kind of stimuli. The most accredited pathogenetic hypothesis predicts, in fact, that various factors (viruses, toxins, autoimmune phenomena, neuro-endocrine substances, etc.), acting on a genetically predisposed soil, can cause an endothelial lesion with a breakdown of the balance between vasodilators/antimitogens factors and vasoconstrictor/mitogenic factors in favor of the latter.<sup>(1)</sup>



**Figure 1.** Pathogenetic hypothesis of pulmonary arterial hypertension.

A vicious circle would therefore be triggered, characterized by vasoconstriction, myointimal proliferation and activation of the coagulation system, leading to the development of characteristic lesions of the disease (Figure 2):<sup>(26)</sup>

- hypertrophy of the media;
- hypertrophy of the intima, sometimes with laminar proliferation and with the possible association of fibrosis or fibrinoid necrosis phenomena;
- plexiform lesions (angiomatous formations originating from the muscular arteries, often completely obstructed by the intima lesions already described);
- in situ thrombosis.



**Figure 2.** Characteristic arteriolar lesions of pulmonary arterial hypertension: a-c) Plexiform lesions; d) Atypical fibrovascular lesions; e) Recent thrombotic lesion; f) Fully organized thrombotic lesion; g) Concentric, non-laminar fibrosis of the intima; g) Eccentric fibrosis of the intima; h) Hyperplasia of the media and collagen-rich fibrosis of the adventitia (arrows); i) Concentric laminar fibrosis of the intima (onion-skin lesions) (from Humbert et al, Eur Respir J 2019;53:1801887).<sup>(26)</sup>

From a clinical point of view, PAH is a syndrome whose main manifestations are dyspnea and right heart failure. In the early stages of the disease, the right ventricle tends to adapt to the increased afterload (ventricular-arterial coupling) by increasing contractility without or with a minimum increase in the right heart size, although an inadequate ventricular-arterial coupling may cause a reduction in aerobic exercise capacity even in the early stages of the disease, limiting the maximum cardiac output. In the more advanced stages, the RV systolic function fails to remain coupled to increased afterload and a progressive right heart dilation develops. In addition, diastolic dysfunction occurs due to myocardial fibrosis and sarcomeric stiffening. All these changes lead to a reduction in the right ventricular output, an increase in the right ventricular filling pressures and a reduced left ventricular (LV) filling, with a subsequent reduction in systemic pressure and an altered ventricular systolic interaction. Such pathophysiological alterations account for PAH typical effort dyspnea and venous congestion.<sup>(2,27,28,29)</sup>

The prognosis of IPAH patients is poor in the short term, with a five-year survival of approximately 40%. In associated forms, the presence of pulmonary arterial hypertension represents a negative prognostic factor regardless of the underlying pathology. Lung transplantation represented, until the 1990s, the only alternative for patients who did not respond to traditional therapy (digitalis, diuretics, anticoagulants, and Ca-antagonists in the indicated cases). In the last two decades, specific drugs have become available (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase agonists, selective prostacyclin receptor agonists) that have radically changed the approach to pathology and awakened the clinician's interest.

**Table 1.** Diagnostic classification of pulmonary hypertension (from Galie et al, Eur Heart J 2016; 37:67-119).<sup>(18)</sup>

<p><b>1. Pulmonary arterial hypertension</b></p> <ul style="list-style-type: none"> <li>1.1 Idiopathic</li> <li>1.2 Heritable               <ul style="list-style-type: none"> <li>1.2.1 <i>BMPR2</i> mutation</li> <li>1.2.2 Other mutations</li> </ul> </li> <li>1.3 Drugs and toxins induced</li> <li>1.4 Associated with:               <ul style="list-style-type: none"> <li>1.4.1 Connective tissue disease</li> <li>1.4.2 Human immunodeficiency virus (HIV) infection</li> <li>1.4.3 Portal hypertension</li> <li>1.4.4 Congenital heart disease</li> <li>1.4.5 Schistosomiasis</li> </ul> </li> </ul>	<p><b>3. Pulmonary hypertension due to lung diseases and/or hypoxia</b></p> <ul style="list-style-type: none"> <li>3.1 Chronic obstructive pulmonary disease</li> <li>3.2 Interstitial lung disease</li> <li>3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern</li> <li>3.4 Sleep-disordered breathing</li> <li>3.5 Alveolar hypoventilation disorders</li> <li>3.6 Chronic exposure to high altitude</li> <li>3.7 Developmental lung diseases</li> </ul>
<p><b>1'. Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomas</b></p> <ul style="list-style-type: none"> <li>1'.1 Idiopathic</li> <li>1'.2 Heritable               <ul style="list-style-type: none"> <li>1'.2.1 <i>EIF2AK4</i> mutation</li> <li>1'.2.2 Other mutations</li> </ul> </li> <li>1'.3 Drugs, toxins and radiation induced</li> <li>1'.4 Associated with:               <ul style="list-style-type: none"> <li>1'.4.1 Connective tissue disease</li> <li>1'.4.2 HIV infection</li> </ul> </li> </ul>	<p><b>4. Chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions</b></p> <ul style="list-style-type: none"> <li>4.1 Chronic thromboembolic pulmonary hypertension</li> <li>4.2 Other pulmonary artery obstructions               <ul style="list-style-type: none"> <li>4.2.1 Angiosarcoma</li> <li>4.2.2 Other intravascular tumors</li> <li>4.2.3 Arteritis</li> <li>4.2.4 Congenital pulmonary arteries stenoses</li> <li>4.2.5 Parasites (hydatidosis)</li> </ul> </li> </ul>
<p><b>1''. Persistent pulmonary hypertension of the newborn</b></p>	<p><b>5. Pulmonary hypertension with unclear and/or multifactorial mechanisms</b></p> <ul style="list-style-type: none"> <li>5.1 Haematological disorders: chronic haemolytic anaemia, myeloproliferative disorders, splenectomy</li> <li>5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis, neurofibromatosis</li> <li>5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders</li> <li>5.4 Others: pulmonary tumoral thrombotic microangiopathy, fibrosing mediastinitis, chronic renal failure (with/without dialysis), segmental pulmonary hypertension</li> </ul>
<p><b>2. Pulmonary hypertension due to left heart disease</b></p> <ul style="list-style-type: none"> <li>2.1 Left ventricular systolic dysfunction</li> <li>2.2 Left ventricular diastolic dysfunction</li> <li>2.3 Valvular disease</li> <li>2.4 Congenital / acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies</li> <li>2.5 Congenital /acquired pulmonary veins stenosis</li> </ul>	

LEGEND - *BMPR2*: bone morphogenetic protein receptor, type 2; *EIF2AK4*: eukaryotic translation initiation factor 2 alpha kinase 4; *HIV*: human immunodeficiency virus.

## 2 - THE RIGHT VENTRICLE

### 2.1 ANATOMY, PHYSIOLOGY AND PATHOPHYSIOLOGY

In mammals and birds the RV is a thin-walled flow generator designed to allow the entire systemic venous return to undergo gas exchange in the pulmonary circulation, which is a separate high-flow, low-pressure system.<sup>(30)</sup>

In the second century Galen described the RV as a simple conduit through which part of the blood reached the lungs to provide nourishment, while the remaining part of blood passed into the left ventricle through invisible pores of the interventricular septum, to form the "vital spirit".<sup>(31)</sup>

In the thirteenth century, Ibn Nafis challenged the existence of the pores in the septum, stating for the first time that all the blood had to pass through the lungs to pass from the RV to the LV.<sup>(31,32)</sup> Ibn Nafis also believed that RV function was to thin the blood to make it suitable for mixing with the air in the lungs.

It was only in 1616 that Sir William Harvey described for the first time the real function of the right ventricle in his treatise *De Motu Cordis*, stating: "It may be said that the right ventricle is made for the sake of the lungs, and for the transmission of blood through them, not for their nutrition".<sup>(33,34)</sup>

In the following centuries, the emphasis that cardiology put on the study of left ventricular physiology led to overlook the study of right ventricular function. This neglect was probably due to both the conception of the RV as a simple passive conduit transferring blood from the venous system to the LV, and to RV geometric conformation, not allowing, especially in the past, an adequate and exhaustive morphological study.

In the 40s of the twentieth century, some researchers hypothesized that human circulation could have functioned adequately without the contribution of right ventricular contraction. Their studies, however, were based on a so-called open model of dog pericardium, and omitted to consider the complex nature of ventricular interaction.<sup>(35,36)</sup>

Between the 50s and 70s, instead, numerous heart surgeons, performing palliative procedures to obviate hypoplastic right heart, finally recognized the importance of RV function.<sup>(37,38)</sup>

In 2006, the National Heart, Lung and Blood Institute set the study of the physiology of the right ventricle as a priority of cardiovascular research.<sup>(39)</sup> Thus, in more recent years, the importance of RV has also been recognized in heart failure, in the myocardial infarction of the right ventricle, in congenital heart disease as well as, obviously, in pulmonary hypertension. Furthermore, the progress achieved in echocardiography and magnetic resonance imaging provided new tools the study of right heart chambers' anatomy and physiology.<sup>(40)</sup>

The RV is placed anteriorly to the LV, just behind the sternum. As already stated, it has a complex geometry, roughly having the shape of a pyramid, triangular when viewed from the side and crescent shaped when viewed in cross section with the interventricular septum, which is a main determinant of the shape. In fact, under normal loading and electrical conditions, the septum is concave toward the LV in both systole and diastole.<sup>(34)</sup>

The RV can be described in terms of 3 anatomical components, presenting different embryological origin and delimited by the supraventricular crest: (1) the inlet, which consists of the tricuspid valve, chordae tendineae, and papillary muscles, (2) the trabeculated apical myocardium, and (3) the infundibulum, or conus, which corresponds to the smooth myocardial outflow region. RV mass is approximately one sixth that of the LV, with thinner walls and a higher surface-to-volume ratio. In the RV, muscle fibers are mainly longitudinally aligned from LV apex to tricuspid ring, and arranged in continuity with the LV musculature, for this reason RV contraction pattern is mainly longitudinal.<sup>(34)</sup>

Thanks to its shape and structure, the RV is an easily dilatable chamber with an internal volume comparatively inferior to the endocardial surface.

The ability of both ventricles to maintain a normal cardiac output, ensuring sufficient

perfusion to the organs, depends on three key factors: the contractile state of myocardial tissue, the pre-load, which represents the initial distension of cardiac myocytes before contraction, and the after-load, defined as the load against which the heart has to allow the systolic expulsion of the blood.<sup>(34)</sup>

Furthermore, right ventricular performance is directly influenced by the functional state of the left ventricle due to the phenomenon of ventricular interaction. In fact, about one third of the force generated in the RV is determined by the contraction of the LV.<sup>(41)</sup>

Right ventricular contraction is strongly conditioned by the increase in after-load, being able to maintain an adequate cardiac output for a rather limited range of pulmonary vascular resistance. On the contrary, it can better tolerate volumetric overload, which alters ventricular geometry, but does not affect the ejection pattern.<sup>(42)</sup>

The particular hemodynamic involvement of the right heart has direct implications on the phases of the RV cardiac cycle. In fact, normally the low end-diastolic pressure in the pulmonary artery is quickly overcome by the pressure rise in RV during systole, with a very short and often absent isovolumetric contraction time.<sup>(34)</sup> The isovolumetric relaxation phase (IVRT) is also generally very short or absent, probably due to the high capacitance of the pulmonary circulation, which at the end of the right injection, despite the drop in pressure in the RV until the closure of the pulmonary valve, maintains the ejection of the blood preserving its momentum.<sup>(34)</sup> Therefore, a measurable IVRT interval can be considered an indicator of increased RV filling pressures.


Intrinsic contractile dysfunction, changes in loading conditions beyond the physiological limits, as well as an altered LV performance, can have negative effects on RV function. There are many possible mechanisms leading to progressive right ventricular dysfunction (Figure 3), including myocardial ischemia or infarction. Arrhythmogenic cardiomyopathy (ARVC) may also be associated with a global and regional reduction in RV performance.<sup>(42)</sup>

Acute pressure overload, which occurs during pulmonary embolism, can determine acute



RV failure with dramatic clinical consequences, given its poor ability to tolerate such condition.

Chronic overload, on the other hand, produces an increase in right myocardial mass (hypertrophy) and a modification of the chamber geometry that temporarily reduces wall stress, but in the long term leads to right ventricular dysfunction.<sup>(42)</sup> Volume overload is a better tolerated condition, but if sustained over time it can ultimately lead to RV failure.



**Figure 3.** Scheme of the pathophysiological mechanisms of right ventricular dysfunction (form Haddad et al, Circulation 2008;117:1717-31).<sup>(42)</sup>

LEGEND - *LM*: left main coronary artery; *LV*: left ventricle; *PFO*: patent foramen ovale; *PH*: pulmonary hypertension; *TR*: tricuspid regurgitation.


## **2.2 IMPACT OF PULMONARY HYPERTENSION ON THE RIGHT VENTRICLE AND RIGHT HEART FAILURE**

The structure of the RV is not adequate to cope with a sudden increase in pulmonary vascular resistance, such as in massive acute pulmonary embolism,<sup>(43)</sup> while in case of chronic increase, such as PAH, the RV is able to adapt to the progressive increase in PVR by increasing contractility and remodeling, with mechanisms similar to those of the LV.<sup>(44)</sup> Sustained changes in load are associated with a homeometric contractility adaptation described by Anrep's law of the heart.<sup>(45)</sup> The homeometric adaptation is associated to the development of myocardial hypertrophy, which increases contractile strength and reduces wall tension. However, if the pressure overload is too high or too prolonged, homeometric adaptation is no longer sufficient, and the heterometric adaptation of Starling comes into play, at the cost of an increase in RV volume and filling pressures.<sup>(45)</sup> This pathophysiological mechanism explains the characteristic clinical picture of PAH: in fact, right heart failure can be defined as a dyspnea-fatigue syndrome with eventual systemic congestion, caused by the inability of the RV to maintain adequate cardiac output using Anrep's homeometric adaptation, in response to metabolic demand, without the use of Starling's heterometric adaptation.<sup>(44)</sup> In this definition, cardiac output is not necessarily low but is low relative to oxygen uptake or aerobic exercise capacity, and vascular congestion is implicit.<sup>(27)</sup>


## **2.3 RV SYSTOLIC FUNCTION AND VENTRICULAR-ARTERIAL COUPLING**

Right ventricular function is a crucial aspect of the pathophysiology of PAH, but its study cannot prescind from RV in relation to the after-load against which it has to work. Hence, the key concept of ventricular-arterial coupling, or a measure of the adequacy of cardiac and vascular function coupling.

The gold-standard measurement of cardiac contractility in vivo, and therefore for the evaluation of the ventricular function independently of the pre-load, is the maximal elastance ( $E_{max}$ ), or the maximum value of the ratio of ventricular pressure to volume during the cardiac cycle.<sup>(44)</sup> In the left ventricle the  $E_{max}$  coincides with the tele-systole (end-systolic elastance or  $E_{es}$ ) and is therefore equal to the ratio between end-systolic pressure (ESP) and end-systolic volume (ESV) (ESPVR: end systolic pressure-volume relationship). The  $E_{es}$  is measured at the upper left corner of a square-shaped pressure-volume loop; this angle represents the point where the cardiac cycle (ejective heartbeat) corresponds to the tension-length relationship (in a hypothetical non ejective cycle).<sup>(46)</sup> Because of the low pulmonary vascular impedance, the normal RV pressure-volume loop has a triangular shape, and  $E_{max}$  occurs before the end of ejection, or end systole. However, afterload increased in PAH changes the shape of RV pressure-volume curve (which tends to assume a quadrangular aspect as in the LV), therefore the  $E_{max}$  is closer to the peak systolic pressure (Figures 4-6).




**Figure 4.** Normal triangular-shaped RV pressure-volume curve, in which maximum elastance ( $E_{es}$ , point A) occurs before the end of systole (from Naeije R, *Pulm Circ* 2014;4:395-406)<sup>(26)</sup>




**Figure 5.** Family of pressure-volume curves of a subject with idiopathic pulmonary arterial hypertension (from Naeije R, *Eur Respir Rev* 2014;23:476-487)<sup>(27)</sup>

A satisfactory measurement of  $E_{max}$  for both ventricles may be obtained from the generation of a family of pressure-volume curves created with progressively decreasing venous returns (via progressive occlusion of the inferior vena cava with a balloon), as shown in Figures 5 -7.<sup>(47)</sup>



**Figure 6.** Family of RV pressure-volume curves obtained by progressively reducing venous return; ESPVR (end-systolic pressure-volume relationship) and EDPVR (end-diastolic pressure-volume relationship) define RV systolic and diastolic function (from Maughan WL et al, *Circ Res* 1979;44:309-315).<sup>(47)</sup>




**Figure 7.** Schematic representation of the  $E_{es}/E_a$  relationship in a family of pressure-volume curves.

Since the realization of pressure-volume curves, requiring invasive assessments, is difficult to perform at the patient's bedside, if not contraindicated, the single-beat method was developed, initially for the LV,<sup>(48)</sup> but later also for RV evaluation.<sup>(49)</sup> This method assumes that the ESPVR is the same in ejective and isovolumic heartbeats, and that maximum pressure of an isovolumic beat ( $P_{max}$ , ie the pressure that the ventricle would generate during a non-ejective beat at the end-diastolic volume) may be extrapolated from normal ejective beats. As for the RV, therefore,  $P_{max}$  is calculated from a non-linear extrapolation of the early and late portions (isovolumic portions) of RV pressure curve, an integration of pulmonary flow or a direct measurement of RV volume curve, and

synchronization of the signals. The  $E_{max}$  is estimated by the slope of a straight line tangent from  $P_{max}$  to the pressure-volume curve (Figure 8). An animal model showed an excellent correspondence between the calculated  $P_{max}$  and the measured  $P_{max}$  directly clamping the trunk of the pulmonary artery for a heartbeat.<sup>(49)</sup>

On the other side, the afterload can be measured as maximum wall tension, integration of forces opposing ventricular ejection or hydraulic load, and as arterial elastance ( $E_a$ ).  $E_a$  is defined as the relationship between  $E_{max}$  pressure and stroke volume (SV). The interesting aspect of the  $E_a$  is that it corresponds to the hydraulic load faced by the RV, and it can be calculated together with the  $E_{max}$  on the same pressure-volume curve. In other words, it represents the RV afterload perceived by the same right ventricle (Figures 7-8).

Therefore, the afterload-corrected contractility is defined by  $E_{max}/E_a$  ratio, and the ideal mechanical coupling between RV and pulmonary arterial system is defined by an  $E_{max}/E_a$  ratio of 1.5-2.<sup>(45)</sup>



**Figure 8.** Pressure-volume relationship illustrating the concepts of ventricular elastance ( $E_{es}$ ), arterial elastance ( $E_s$ ) and maximum isovolumic pressure used to estimate  $E_{es}$  with the single-beat method (from Vonk-Noordegraaf A et al, JACC 2013;62(25 Suppl):D22-33).<sup>(2)</sup>

However, the single-beat method requires invasive RV pressure curve measurement and RV volume measurement by cardiac MR, not always available in daily clinical practice. Therefore, several methods have been recently developed for the simplified calculation of

right ventricular-arterial coupling; an example is given by the formula:  $E_{max}/E_a = (ESP/ESV)/(ESP/SV) = SV/ESV$ , which we have already used in a previous study.<sup>(50)</sup>

## **2.4 RIGHT VENTRICULAR DIASTOLIC FUNCTION**

Even though systolic function adaptation to afterload is central to the occurrence of RV failure signs and symptoms in PAH, diastolic function changes must also be taken into consideration. Indeed, RV diastolic dysfunction impairs RV filling and increases diastolic RV and right atrial pressures, leading to fluid retention and systemic congestion. Thus, the study of both systolic and diastolic RV ventricular functions is required to fully understand the pathophysiology and the clinical aspects of the disease.

Diastolic dysfunction is characterized by altered filling patterns, prolonged relaxation, and intrinsic diastolic stiffness, and it can be attributed to several contributing factors, such as RV overload impairing per se RV diastolic relaxation, hypertrophy and fibrosis, reducing RV compliance and filling, as well as changes in RV sarcomeres.

In practice, a large number of parameters has been used to describe RV diastolic function in PAH. Right atrial pressure (or RV end-diastolic pressure) is probably the parameter that has been most related to outcome in PAH.<sup>(51)</sup> It can be measured directly during right heart catheterization, thus requiring invasive measurement, or estimated noninvasively by echocardiographic assessment of inferior vena cava diameter and collapsibility. Echocardiography is able to provide many other measurements of diastolic function, including RV Doppler-derived filling profiles (isovolumic relaxation time, transtricuspid E/A waves ratio or tricuspid annulus tissue Doppler E'/A' waves); relaxation-phase indices (dP/dt minimum and the time constant of isovolumic pressure decay); increased right atrial or RV surface areas on apical four-chamber views; RV end-diastolic volume (which can be more accurately evaluated by cardiac MRI); altered LV eccentricity index on a parasternal short axis view; estimates of RAP from RV diastolic function indices (annular tricuspid E/E'

ratio, annular TDI relaxation time), pericardial effusion; Tei index (ratio of isovolumic time intervals to ventricular ejection time, integrating diastolic and systolic function).<sup>(52,53)</sup>

Several studies have demonstrated the prognostic value of these measurements.<sup>(54,55,56)</sup> However, all these parameters provide information only on relaxation velocities and filling, and are all highly dependent on loading condition, so they cannot provide any information on true RV diastolic function. For these reasons, they can be considered only as indirect or surrogate markers of RV diastole.

RV diastolic function can be described in load-independent manner by a diastolic elastance ( $E_{ed}$ ) curve determined by a family of pressure-volume loops at variable loading (Figure 6).<sup>(47)</sup> The diastolic pressure-volume relationship is curvilinear, thus the straight line approach as a description is not sufficiently accurate. Several formulas have been proposed, and the most adequate description is obtained by fitting the relation with an exponential curve through the diastolic pressure-volume points, with the formula  $P=\alpha(e^{\beta V}-1)$ , where  $\alpha$  and  $\beta$  are curve-fitting constants.<sup>(30, 57)</sup> As for systolic function description,<sup>(49)</sup> to avoid building multiple pressure-volume loops by partial vena cava occlusion, which is not safe in PAH patients, a single-beat method has been developed to determine  $E_{ed}$ .<sup>(5)</sup> The latter now can be calculated as  $E_{ed}=\alpha\beta e^{\beta V_{ed}}$ , where  $V_{ed}$  is the end-diastolic volume (EDV). By this method, RV diastolic stiffness was found to be significantly increased in PAH patients, and histological analysis found important contributions from increased collagen and intrinsic stiffening of the RV cardiomyocyte sarcomeres, reduced titin and troponin I (cTnI) phosphorylation, increased titin stiffness, and altered levels of phosphorylation of  $Ca^{2+}$ -handling proteins.<sup>(5,6)</sup> The so-defined diastolic stiffness predicts outcome in PAH as well as the more complex  $\beta$  calculation, and it is closely associated with disease severity and clinical progression,<sup>(7)</sup> but also with  $E_{es}$ .<sup>(5)</sup> Moreover, recent studies have shown a significant association between single-beat  $E_{ed}$  and ventilatory efficiency measured at CPET,<sup>(58)</sup> between RV single-beat stiffness and MRI-derived strain parameters

of the RV,<sup>(10)</sup> and between RV single-beat stiffness and significant backward flow in the vena cava, which is a well-recognized clinical hallmark of right ventricular failure, measured at MRI in PAH patients.<sup>(59)</sup>

More recently, there are been other attempts to measure RV stiffness by imaging technique, like the echocardiographic index of RV operating stiffness using atrial-systolic descent of the pulmonary artery-RV pressure gradient derived from pulmonary regurgitant velocity (PRPGDAC) and tricuspid annular plane movement during atrial contraction (TAPMAC); however it has been evaluated in a population of patients with various cardiac diseases, and it still requires invasive measurement of RV end-diastolic pressure and RV pressure increase during atrial contraction.<sup>(60)</sup> Another study conducted on a small population of pediatric PAH patients showed, compared to controls, higher stiffness/elastic recoil and inferior cross-bridge relaxation measured by the kinematic model-based parameters obtained from the transtricuspid E-wave.<sup>( 61 )</sup> The limit of these echocardiographic evaluations is the use of complex derived measurement which are susceptible of imprecision and highly operator dependent, so often inaccurate and poorly reliable.

## **2.5 VENTRICULAR INTERACTION**

Finally, both systolic and diastolic RV function also have to be understood in the context of its direct and indirect interactions with LV function, as ventricular interdependence plays an essential part in the pathophysiology of RV dysfunction.<sup>(27)</sup>

Direct interaction, or ventricular interdependence, is defined as the forces that are transmitted from one ventricle to the other through the myocardium and pericardium, independent of neural, humoral or circulatory effects.<sup>(41)</sup>

Diastolic ventricular interaction refers to the competition for space within the nondistensible pericardium when the RV dilates, altering LV filling and possibly causing inadequate cardiac



output response to metabolic demand. Right heart catheterization and imaging studies have shown that in severe PH patients, mPAP and LV peak filling rate are altered in proportion to decreased RV ejection fraction.<sup>(62)</sup>

Systolic interaction refers to positive interaction between RV and LV contractions. It can be shown experimentally that aortic constriction, and enhanced LV contraction, markedly improves RV function in animals with pulmonary arterial banding.<sup>(63)</sup> Similarly, in electrically isolated ventricular preparations in the otherwise intact dog heart, LV contraction contributes a significant amount (about 30%) to both RV contraction and pulmonary flow.<sup>(64)</sup> This is explained by a mechanical entrainment effect, but also by LV systolic function determining systemic blood pressure, which is an essential determinant of RV coronary perfusion. Increased RV filling pressures and excessive decrease in blood pressure may be a cause of RV ischaemia and decreased contractility.

An additional cause of negative ventricular interaction is regional dyssynchrony and inter-ventricular asynchrony with post-systolic contraction or “shortening”, which has been shown to develop in parallel with increased PAP and contributes to altered RV systolic function and LV under-filling.<sup>(65,11,12)</sup>

### **3. ROLE OF DOPPLER ECHOCARDIOGRAPHY IN THE STUDY OF PULMONARY ARTERIAL HYPERTENSION**

Although hemodynamic invasive study of the pulmonary circulation by right heart catheterization represents the gold standard for the diagnosis of PH, and it is still fundamental for patient evaluation during follow-up, noninvasive imaging plays a key role in both the diagnosis and management of PH patients, allowing the evaluation not only of the pulmonary pressures, but also of the cardiopulmonary unit function.<sup>(66)</sup> Echocardiography, magnetic resonance imaging (MRI), computed tomography, and positron emission tomography (PET) have a complementary role in the diagnosis of PH, but also in identifying prognostic factors able to support clinicians in treatment decision-making in PAH patients.

MRI has emerged as the gold standard for quantifying volumes, function, and flow in the right side of the heart. However, echocardiography is the mainstay in the assessment of hemodynamic and ventricular function in PH, thanks to the practicality of use in all patients, including bedside and in the strict follow-up.

The fields of application of Doppler echocardiography in pulmonary hypertension are several and include:

- diagnosis and screening of populations with clinical suspicion of PH;
- functional assessment of the right ventricle;
- evaluation of concomitant cardiac alterations, such as the presence of congenital heart disease, valvular heart disease or cardiomyopathies, possibly responsible of the elevated pulmonary artery pressure;
- evaluation of the effectiveness of therapeutic interventions.

### **3.1 NON-INVASIVE ASSESSMENT OF THE RIGHT VENTRICLE: STANDARD DOPPLER ECHOCARDIOGRAPHY**

Mono and two-dimensional echocardiography can provide both morphological and functional measurements of the right ventricle. M-mode is commonly used to estimate RV dimensions, the thickness of the free wall, its excursions and wall thickening; Doppler analysis provides measures of systolic function in the outflow tract and diastolic function in the transtricuspid inflow.

From a qualitative point of view, RV dimensions can be better defined if it is considered anatomically distinct in two portions, a body (from the tricuspid to the apex) and an outflow tract (located anteriorly and medially), recognizable in the parasternal short-axis view on the great vessels.<sup>(67)</sup>

In the parasternal short-axis view, the systolic and diastolic eccentricity indices of the left ventricle (LV-EI<sub>s</sub> and LV-EI<sub>d</sub>, respectively) provide a datum of fundamental importance, also concerning the bi-ventricular interaction. They are defined as the ratio of the antero-posterior diameter to the septum-lateral one measured both in systole and in diastole. In normal individuals this dimensional ratio corresponds to unity, being the cross-section of the left ventricle approximately circular. This view also allows to identify the presence and the degree of the paradoxical interventricular septal motion, which develops when the normal gradient of end-diastolic pressure between the two ventricles is reversed.

The 4-chamber apical view represents a fundamental approach to assess RV size and function. In this window a simple and quick way to appreciate RV dimensions is the visual comparison with the LV.

The study of the RV in the subcostal approach, necessary in patients with poor acoustic windows (such as in the presence of chronic obstructive pulmonary disease), provides additional information associated with visualization of the inferior vena cava (diameter and

respiratory collapsibility).

An integrated approach is always recommended in the various views to obtain a complete study, especially in the evaluation of patients with pulmonary hypertension.

The methods of quantitative evaluation of RV indices of systolic function, in particular of the ejection fraction (EF), present several problems due to the anatomical and functional characteristics of the RV.<sup>(68)</sup> Given the difficulties in finding an optimal approach for the calculation of the volumes and ejection fraction, some simple mono and bidimensional parameters have been introduced, that have been able to predict RV systolic function in clinical studies. Right ventricular fractional area change (RVFAC), measured with the formula:  $RVFAC = (RVEDA - RVESA) / RVEDA \times 100$  (where RVEDA = right ventricular end diastolic area, RVESA = right ventricular end systolic area), has shown a good correlation with RVEF measured by CMR.<sup>(69)</sup>

The excursion of the tricuspid ring during systole (TAPSE - tricuspid anular plane systolic excursion) reflects the systolic base-apex shortening of the RV, which can be determined by two-dimensional echocardiography, but also with simple M-mode by measuring the excursion of the lateral wall of the tricuspid ring. TAPSE is a practical, accurate and reproducible index that correlates with the RVEF measured by radionuclide angiography.<sup>(70)</sup>

Doppler analysis of RV outflow, which can be performed in the so-called great vessels parasternal view, allows the recording of RV systolic velocity profile by placing pulsed Doppler sample volume, guided by the color signal, immediately above the pulmonary valve. In this way it is possible to measure the peak systolic velocity (m/s), the velocity-time integral (m) and the systolic outflow times of the RV: the pre-ejection period (R-PEI), from the beginning of the QRS complex of the reference ECG trace at the beginning of the Doppler signal of the systolic outflow; the acceleration time (AT), from the beginning to the peak of the systolic ejection; the ejection time (ET), from the beginning to the end of the ejection (all in ms).

The Doppler of the right inflow, like transmitral Doppler, measures the flow velocities through the tricuspid valve and reflects the pressure gradients leading RV filling during diastole. Measurements are recorded in the apical 4-chamber view: E and A peak velocity (m/s), E/A ratio, E deceleration time (ms). More than the transmitral pattern, the transtricuspid flow rates are influenced by breathing, with an increase in E and the E/A ratio and shortening of the deceleration time during inspiration.

Tissue Doppler echocardiography is able to provide further indices of RV function. The RV systolic excursion velocity, or S', is a simple and reproducible method to assess RV free wall function; it is performed in apical 4-chamber window by placing the pulsed Doppler sample volume in either the tricuspid annulus or the middle of the basal RV free wall, and a value < 10 cm/s should raise the suspicion for abnormal RV systolic function.<sup>(71)</sup> Myocardial acceleration during isovolumic contraction (RV IVA) is defined as the peak isovolumic myocardial velocity divided by time to peak velocity and it is measured at the lateral tricuspid annulus, and it has been demonstrated to correlate with the severity of the disease in many condition affecting right heart function.<sup>(71)</sup> The tricuspid E/E' ratio represents an index of RV diastolic function.<sup>(71)</sup>

### **3.2 NON-INVASIVE ESTIMATION OF PULMONARY ARTERIAL PRESSURE**

The rationale of the PAP Doppler estimate lies in the following factors:

- 1 - the frequency variation of the Doppler signal reflected by the moving red blood cells, allowing the acquisition of the maximum instantaneous velocity through the valve orifices, from which it is possible to derive the pressure gradient between cardiac chambers (Bernoulli equation);
- 2 - the maximum instantaneous velocities of the tricuspid regurgitation jet and of the pulmonary diastolic regurgitation jet, which accurately reflect the maximum pressure gradients between RV and right atrium, and between RV and pulmonary artery;

3 - the possibility to derive the value of the systolic and diastolic PAP (sPAP and dPAP, respectively) by adding the respective pressure gradients to right atrial pressure (RAP), whose value can be estimated by evaluating diameter and respiratory collapsibility of the inferior vena cava in the subcostal view, in the portion of the vessel closest to the entrance of the right atrium; the measurement of the caval diameter is performed during a normal respiration, and the percentage caliber variation is determined in the inspiratory phase compared to expiration.

sPAP corresponds approximately to RV systolic pressure in the absence of pulmonary artery stenosis and obstruction of RV outflow tract, and it can therefore be measured with techniques for RV pressure estimation.

RV pressure is obtained by adding mean RAP to the peak of the systolic pressure gradient between the RV and the right atrium, calculated as  $4V^2$  according to the simplified Bernoulli equation, where V represents the value of the systolic peak velocity of tricuspid regurgitation at the continuous wave Doppler.<sup>(71)</sup>

dPAP is calculated by adding the right atrial pressure values to the diastolic pressure gradient between the pulmonary artery and the RV.<sup>(71)</sup>

Mean PAP is the average PAP value during the cardiac cycle. Since the systole is shorter than diastole, the mPAP is slightly lower than the arithmetic mean between sPAP and dPAP. It can be determined by integrating the area of the pressure curve. In practice, it is possible to obtain a measurement of mPAP by deriving it from the sPAP and dPAP.<sup>(71)</sup> Alternatively, mPAP can be calculated by measuring the protodiastolic flow rate of pulmonary regurgitation and the corresponding pressure gradient. The protodiastolic pressure gradient between pulmonary artery and RV correlates well with mPAP.<sup>(71)</sup>

To obtain an echocardiographic quantitative estimate of sPAP, the presence of tricuspid regurgitation is indispensable. The velocity of normal tricuspid regurgitation is up to 2.8 m/s, higher values indicate the possibility of pulmonary hypertension, pulmonary stenosis or

obstruction of ventricular outflow. It should be kept in mind that in patients with pre-existing right ventricular dysfunction, with pulmonary hypertension or biventricular insufficiency, a decrease in tricuspid regurgitation velocity indicates a worsening in RV systolic dysfunction, thus representing a very important negative prognostic factor.

The prevalence of tricuspid regurgitation increases with increasing PAP. Unfortunately, not all patients presenting tricuspid regurgitation have a flow profile suitable for performing all measurements, due to the presence of factors limiting the accurate visualization of the profile, such as disease severity, obesity and concomitant lung diseases.

### **3.3 PROGNOSTIC VALUE OF RIGHT VENTRICULAR DYSFUNCTION**

In the natural history of pulmonary hypertension, it is not the increase in pulmonary pressure, but the reduction in cardiac output that determines clinical deterioration. Although the increase in pulmonary vascular resistance is the cause of the pathology, it is indeed RV dysfunction that leads affected patients to death, in fact mPAP value has only a modest prognostic significance.<sup>(18)</sup>

The prognostic role of standard echocardiographic evaluation of structural changes and of direct or indirect indices of right ventricular function is therefore evident.

Raymond et al<sup>(72)</sup> demonstrated that, in addition to the NYHA functional class and the reduction in exercise tolerance, the presence of pericardial effusion, right atrial dilation and eccentricity index are important prognostic factors for survival of PH patients.

Given the importance of the longitudinal fibers in RV systolic function, TAPSE has shown an independent and incremental prognostic power: in a study conducted by Forfia et al,<sup>(73)</sup> a cut-off value  $\leq 18$  mm was significantly associated with a worse prognosis in a population of PAH patients. Subsequent studies have recognized a prognostic value to right heart dimensions,<sup>(74)</sup> RV estimated diastolic pressure,<sup>(75)</sup> maximum velocity during isovolumic contraction (IVV)<sup>(76)</sup> and dP/dT.<sup>(79)</sup>

## **4. DEFORMATION AND DYSSYNCHRONY OF THE RIGHT VENTRICLE**

### **4.1 THE CONCEPT OF STRAIN**

The strain is the deformation of an object compared to its original size and is expressed as a percentage.

For one-dimensional objects, with only one possible deformation (for example elongation and shortening), the physical definition of strain (S) is the relative variation in length of the object compared to its original length:  $S = (L - L_0) / L_0$ , where L is the length of the object after the deformation and  $L_0$  its original length.<sup>(77)</sup>

The strain rate (SR) is the velocity at which the deformation occurs (S) and is expressed in 1 / s:  $SR = (L - L_0) / L_0 / T$ , where T is the time.<sup>(77)</sup>

The regional strain curve represents the deformation of a given myocardial segment during the entire cardiac cycle. The S / SR parameters are negative when the studied myocardial segment shortens (longitudinal function) or thins (radial function), while they are positive when the studied myocardial segment lengthens (longitudinal function) or thickens (radial function).<sup>(77)</sup>

Myocardial strain and strain rate can be evaluated by tissue Doppler imaging (TDI), magnetic resonance imaging (MRI) and speckle tracking echocardiography (STE).

### **4.2 SPECKLE TRACKING ECHOCARDIOGRAPHY**

It is a new approach to evaluate RV segmental systolic function, overcoming the technical limitations of tissue Doppler imaging,<sup>(78)</sup> since it measures myocardial strain regardless of the angle of incidence, as well as magnetic resonance temporal resolution limits. This method has been validated by sonomicrometry and MR.<sup>(79)</sup>

The literal meaning refers to a system that follows the "speckles" during the cardiac cycle. The speckles are the white and black dots that make up the "texture" of the two-dimensional ultrasound image. Placed in a completely random way, they are the result of the interaction



of ultrasound with myocardial tissue.<sup>(77)</sup>

The principle is not new, in fact the "speckles" could already be followed with the M-Mode technique, deriving their displacement, velocity (both more marked at the base than at the apex) and even the deformation (obviously only along the single-beam line of M-mode echocardiography). This was possible because the M-mode technique has a very high temporal resolution. Today speckles, instead of in a single line, can be recognized in an entire region (the so-called Kernel) and followed throughout the cardiac cycle. This is possible thanks to modern technologies that allow to obtain two-dimensional images with high temporal resolution (of the order of 80-90 frames per second).<sup>(77)</sup>

Once the different regions have been recognized, displacement, displacement velocity, deformation (two contiguous regions approaching or moving away from each other) and the deformation velocity can be calculated (Figure 9) .

The clinical utility of this method has already been established in patients with heart failure undergoing electrical resynchronization treatment.<sup>(80)</sup>




Figure 9. RV strain pattern by 2D-STE of a healthy subject.

### 4.3 SYSTOLIC DEFORMATION AND DYSSYNCHRONY OF THE RIGHT VENTRICLE

Concerning the applications on the right ventricle of echocardiographic methods allowing the valuation of myocardial strain, some studies have shown a good correlation between longitudinal strain measured at tissue Doppler and RV stroke volume at right heart catheterization, and a significant reduction of longitudinal strain in patients with high pulmonary arterial pressures compared to normal controls.<sup>(81)</sup> Compared to the common indices of right ventricular function, such as TAPSE and RVFAC, longitudinal strain could provide an added value, since it offers quantitative data on the real regional function of the whole RV free wall.

Also speckle tracking echocardiography (STE) has been used for the study of right ventricular myocardial deformation, and preliminary studies have shown that it is able to provide results with good correlation with the other RV function indices measured at echocardiography and MRI.<sup>(82)</sup> In more recent years, a study confirmed the reliability and feasibility of a three-dimensional (3D) STE compared to MRI to assess RV volume, RV ejection fraction and the contribution of regional RV function to global function.<sup>(83)</sup>

Speckle tracking echocardiography, compared to the tissue Doppler, besides being independent from insonation angle and not conditioned by the movement of the adjacent segments, has proved to be feasible and highly reproducible even in highly dilated and remodeled ventricles.<sup>(77)</sup> However, it has a lower temporal resolution and a strong dependence on image quality and therefore on the acoustic window.

The method is applied to images recorded in the apical 4-chamber view, mainly allowing the study of the inflow portion of the RV, which is responsible for 85% of the stroke volume.<sup>(84)</sup> In fact, the major determinant of RV pump function is the shortening of the longitudinal fibers that are particularly expressed on its free wall.

Meris et al<sup>(85)</sup> conducted a study on a large number of patients, demonstrating the feasibility of analyzing RV systolic deformation by speckle tracking echocardiography, both

in healthy subjects and in subjects suffering from cardiac pathologies, including pulmonary hypertension. The study documented a good correlation between global longitudinal strain and traditional right ventricular systolic function indices. In particular, a global longitudinal strain cut-off of 19% can non-invasively distinguish normal subjects from those with RV systolic dysfunction.

Another interesting work, published by Borges et al,<sup>(86)</sup> reported the results of a study conducted on 37 patients with pulmonary hypertension, evaluating the parameters of systolic function and deformation of baseline RV and after 1-year therapy with the endothelin receptor antagonist Bosentan, demonstrating an improvement of the invasive hemodynamic parameters and of RV longitudinal strain.

More recent larger studies have demonstrated that RV longitudinal strain in combination with N-terminal pro-brain natriuretic peptide and NYHA functional class provides good discrimination of outcome in PAH.<sup>(87,88)</sup>

A particularly interesting aspect of STE is the possibility to study RV timing of contraction and to evaluate RV regional contractility. The anomalies in RV regional performance are a sensitive measure of its functional status; by influencing chronic pressure overload specifically on regional motility, this pathological condition contributes to the onset of intraventricular dyssynchrony with significant impact on the overloaded ventricle: an incoordinated contraction, in fact, especially in the longitudinal direction, contributes to further reduce RV systolic function.

Preliminary data had suggested the existence of a mechanical contraction delay, calculated by tissue Doppler,<sup>(89)</sup> between the interventricular septum and the free wall of RV in patients with pulmonary hypertension. However, the first studies conducted on the evaluation of intra- and interventricular dyssynchrony were heterogeneous in number and population characteristics, thus leading to conflicting results. In fact, while Schwartz et al<sup>(90)</sup> have demonstrated that the peak of free wall systolic activation at TDI is anticipated with

respect to the septum in PAH patients compared to healthy controls, López-Candalez<sup>(91)</sup> reported a delay in the systolic peak at TDI in affected subjects compared to the control group, on a larger but more heterogeneous sample. The data reported by Kalogeropoulos et al<sup>(92)</sup> agreed with López-Candalez: using STE they have demonstrated a delayed deformation peak of the free wall with respect to the septum and a dyssynchrony index (evaluated as standard deviation of activation of the 6 RV segments) higher in affected subjects than in healthy controls. Furthermore, a study conducted by Marcus et al<sup>(65)</sup> with cardiac tagged MR confirms the delay of RV free wall, in terms not of systolic activation but rather of time at the deformation peak.

A fundamental contribution to the study of RV dyssynchrony has been provided in the last years by our group,<sup>(11,12,13)</sup> which analyzed a larger and more homogeneous population than the previous studies, allowing to evaluate a pure model of afterload mismatch, and defining RV dyssynchrony as the standard deviation of time to peak systolic strain of the 4 RV mid-basal segments (thus eliminating the apical segments, that cause heterogeneity in the results even in healthy subjects). We have shown in a first study that in patients with idiopathic PAH with narrow QRS, RV dyssynchrony is associated with RV dilation and eccentric hypertrophy, suggesting a role of segmental wall stress heterogeneity as a major determinant of mechanical delay.<sup>(11)</sup> Our study also showed that post-systolic shortening contributes to pump dysfunction as an inefficient contraction.<sup>(11)</sup> In a second work we demonstrated that, in a population with idiopathic, inherited and appetite suppressant associated PAH, RV dyssynchrony is an independent prognostic factor and can reverse in case of significant reduction in PVR during specific therapy.<sup>(12)</sup> A subsequent study demonstrated that a comprehensive echocardiography with speckle tracking-derived assessment of the heterogeneity of RV contraction improves the prediction of aerobic exercise capacity in IPAH, and could even explain the reduced effort tolerance sometimes found in PAH patients with preserved traditional indices of RV function.<sup>(13)</sup> Finally, a more

recent study on a small group of healthy subjects demonstrated that RV contraction is inhomogeneous in hypoxia but not during exercise;<sup>(93)</sup> both conditions are characterized by mild increase in pulmonary pressure, since PAP increases more during exercise, RV dyssynchrony in hypoxia may be explained by a combination of mechanical (RV afterload) and systemic (hypoxia) factors, suggesting further insight to explain RV dyssynchrony found in patients with borderline PH.<sup>(94)</sup>

#### **4.4 RIGHT VENTRICULAR STRAIN AND DIASTOLIC FUNCTION**

Speckle tracking has been also applied to the evaluation of diastolic function in the left ventricle: global myocardial peak diastolic strain (Ds) and diastolic strain rate (DSr) at the time of E and isovolumic relaxation combined with E (E/Ds and E/10 DSr) have been recently proposed as novel indices to determine LV filling pressure,<sup>(95)</sup> and strain-derived indices at STE resulted as better predictors of LV end-diastolic pressure compared with TDI in patients with preserved ejection fraction.<sup>(96)</sup>

Nevertheless, to date, systolic strain and dyssynchrony for the study of RV systolic function are the only application of STE to the RV, while the evaluation of diastolic function by this echocardiography method and in general by strain indices has always been neglected.

However, a recent study by Tello and colleagues<sup>(10)</sup> has shown for the first time a significant association between cardiac MRI-derived RV strain parameters and the pressure-volume loop-derived parameters Ees/Ea, Ea, and Eed. RV strain assessed by the novel method of cardiac MR feature tracking was significantly associated with diastolic stiffness (Eed) and afterload (pulmonary arterial stiffness and Ea), suggesting cardiac MR RV strain as a promising indicator of RV-arterial uncoupling and RV diastolic stiffness.

These results should trigger to apply STE analysis of RV strain to the evaluation of RV diastolic function, profiting of the advantage of ST over MRI in terms of temporal resolution and convenience of routine use.

## 5 - EXPERIMENTAL SECTION

### 5.1 AIM OF THE STUDY

Pulmonary arterial hypertension (PAH) is a severe disease characterized by a progressive elevation of pulmonary vascular resistance (PVR), ultimately resulting in right ventricular (RV) dilation and systolic dysfunction leading to heart failure and death.<sup>(1)</sup>

The pathophysiological model of the disease is an afterload mismatch, thus prognosis depends on the ability of the RV to maintain its function in face of increased afterload, underscoring the importance of RV function assessment in clinical practice.<sup>(2)</sup>

Although it is well known that RV systolic adaptation to increased afterload is of main clinical importance, in the last years there has been a focus on the RV diastolic function in PAH.

The study of RV diastolic function has always been rather difficult, as invasive hemodynamic evaluation and imaging studies provide only indirect, highly load-dependent surrogates measurements of RV diastolic function,<sup>(27)</sup> the gold standard load-independent measurement by pressure-volume analysis, able to measure RV diastolic stiffness, is too risky in PAH patients because it requires load modifications by vena cava occlusion,<sup>(47)</sup> while single-beat pressure-volume analysis, though safer, requires invasive measurement and RMI study, not applicable in routine evaluation and not in all patients.<sup>(49)</sup>

Two-dimensional (2D) Speckle Tracking Echocardiography (STE) has gained importance for RV systolic function evaluation in the last years, allowing the evaluation of RV strain and dyssynchrony,<sup>(11,12,13)</sup> but STE study of RV diastolic function has been neglected.

The aim of this thesis is therefore to describe strain-derived right ventricular diastolic patterns by speckle tracking echocardiography and their clinical impact in a large population of idiopathic pulmonary arterial hypertension (IPAH) patients.

## **5.2 METHODS**

### **5.2.1 Population and study protocol**

The initial study population included 118 consecutive IPAH patients referred to our Center. Diagnosis of IPAH had been made according to European guidelines.<sup>(18)</sup> Nine patients with suboptimal echocardiographic images were excluded from all subsequent analyses. Thus, the study group consisted of 108 patients.

Baseline evaluation included medical history, physical examination, a non-encouraged 6-minute walk test (6MWT), right heart catheterization (RHC) and the echocardiographic assessment.

Patients treatment was based on the severity of PAH, in accordance to European guidelines.<sup>(18)</sup> All patients were prospectively followed-up for 24 months with phone calls (every month) and clinical examinations (every 1-3 months) for the presence of clinical worsening (CW), defined as hospitalization for congestive heart failure or death. The first episode of CW was taken into consideration for the analysis.

All patients were included in the study protocol after informed consent. The protocol was approved by the Institutional Review Board for human studies of the Policlinico Umberto I - Sapienza University of Rome.

### **5.2.2 Right Heart Catheterization**

Hemodynamic evaluation was made with standard technique: patients underwent right heart catheterization with a Swan-Ganz triple-lumen thermodilution catheter, in the supine position, with zero calibration at the center of the thorax and detection of pressure at the end of exhalation. Measurements performed included mean pulmonary artery pressure (mPAP), wedge pressure (WP), right atrial pressure (RAP) and cardiac output (CO). Pulmonary vascular resistance (RVP) was calculated with the formula  $(mPAP - WP) / CO$ .

### 5.2.3 Standard Echocardiography

Echocardiographic studies were performed using commercially available equipment (Vivid S6, GE) and acquired within 24 hours from RHC. Standard M-mode, 2D and Doppler images were obtained during breath hold and stored in cine-loop format from 3 consecutive beats. Measurements were performed in accordance with the American Society of Echocardiography Guidelines.<sup>(71)</sup>

The following parameters and derived measures were considered in the analysis: right atrial area (RA area), RV end-diastolic area (RVEDA), RV end-systolic area (RVESA), RV fractional area change % [ $RVFAC=(RVEDA - RVESA)/RVEDA \times 100$ ], tricuspid annular plane systolic excursion (TAPSE), left ventricular systolic and diastolic eccentricity index (LV-El<sub>s</sub> and LV-El<sub>d</sub>, respectively), presence of pericardial effusion. Tricuspid regurgitation was semiquantitatively graded considering the regurgitant jet area at color Doppler imaging.

All reported measurements are the averages derived from three consecutive cardiac cycles. We previously reported on our intra-observer and inter-observer variabilities of these measurements.<sup>(97)</sup>

### 5.2.4 2D Speckle Tracking Echocardiography

#### *Acquisition*

For speckle tracking analysis (EchoPAC workstation 7.0.1, GE Medical Systems), standard grayscale 2D images in the 4-chamber apical view were acquired with a frame rate between 50 and 70 fps (to allow reliable analysis of the software) and digitally stored in 3 beats cine-loop format. The RV endocardial border was manually traced at end-systolic frame. A second larger region of interest (ROI) was then generated, manually adjusted near the epicardium and followed by an automated tracking algorithm from this single frame throughout the entire cardiac cycle. In addition, a fine-tune of the region of interest, by using



a visual assessment during cine-loop playback, was done to ensure that segments were tracked appropriately.

### *Analysis*

To assess the segmental characteristics of the RV, we adopted the 4-segment model, excluding the apical segments for the analysis, because of the high variability of that segments, observed even in normal subjects. This decision is supported by software-related technical issues<sup>(98)</sup> and explained in our previous studies.<sup>(12)</sup>

To describe RV diastolic patterns we considered longitudinal strain and evaluated the time period from peak-systolic strain to return to baseline point-set, for the basal and mid RV free wall segments. Thirty healthy controls, matched for age, gender, and body mass index (BMI), were included to define the normal RV diastolic pattern.

To define intra- and interobserver variability for RV diastolic patterns assignment, 2D speckle tracking measurements were repeated for all patients by the same observer and by a second independent observer.

### **5.2.5 Statistical Analysis**

Continuous data are expressed as mean  $\pm$  standard deviation, and categorical data are expressed as counts and proportions. Two-group comparisons were done with unpaired or paired, two-tailed t tests for means if the data were normally distributed or with Wilcoxon's rank-sum tests if the data were not normally distributed. Chi square or Fisher's exact tests were used to analyze the categorical data.

Regression analysis was performed to assess the relations between echocardiographic and hemodynamic parameters.

Actuarial freedom from episodes of CW was determined by the Life Table method. Kaplan-Meier (product-limit) graphs were used to demonstrate clinical worsening over time.

Cox proportional hazards regression methods were used to identify risk factors for CW.

Because of the large number of variables that were being assessed compared to the relative low number of events occurred, a strict univariate p-value criterion ( $p, 0.05$ ) was used to consider those variables that were initially entered in the multivariable model and included if they improved the likelihood ratio statistic by an amount that corresponded to a p value of  $<0.05$ . This approach was taken to minimize the probability that the value of the calculated test statistic, or an extreme value, had occurred by chance. Collinearity was assessed by using bivariate linear regression between continuous variables or using Wilcoxon tests across categorical variables. When 2 or more selected variables were intimately associated (correlation coefficient  $>0.60$ , as between cardiac index-CI and 6MWT; between mPAP, PVR, RVFAC, TAPSE, global strain, basal and mid RVFW strain; between RAP and pericardial effusion; WHO class and tricuspid regurgitation), the one chosen was that with the greatest Wald statistics. This approach allowed to restrict the candidate variables for the multivariate analysis to 6MWT, RAP, RVEDA, tricuspid regurgitation and basal RVFW strain for Model-1 and to 6MWT, RAP, RVEDA, tricuspid regurgitation and strain-derived diastolic patterns for Model-2.

The proportional-hazards assumptions were assessed with Durbin-Watson test.

The c statistic was calculated for each model and compared by the method of DeLong et al<sup>(99)</sup> to determine the incremental prognostic information of Model-2.

Cohen's kappa ( $k$ ) was used as a measure of inter-observer agreement for categorical scales. The  $k$  represents the proportion of agreement over and above chance agreement and can range from -1 to +1. Based on the guidelines from Altman<sup>(100)</sup> a  $k >0.50$  represents moderate to optimal strength of agreement.

All statistical analysis was performed using SPSS software (version 24.0, IBM) and MedCalc (version 13.3).

## 5.3 RESULTS

Baseline characteristics of the 108 PAH patients are summarized in Table 2. The majority of patients were female, in WHO class III, with severe PAH and impaired effort capacity.

The echocardiographic evaluation at baseline showed severe RV dilation and reduction of systolic function. Most of the patients presented mild to moderate tricuspid regurgitation.

### 5.3.1 2D diastolic patterns in PAH

Speckle tracking imaging of the RV generated strain curves from the basal and middle segments of the RV free wall. Three different diastolic patterns of the corresponding segments on the strain-time curve were identified in our cohort of PAH patients (Figure 10).

Pattern 1 corresponded to a prompt downward shift of the strain-derived curves after peak systolic strain towards the base line, followed by a virtually straight curve to the end of diastole. Interestingly, Pattern 1 was repeatedly found in a cohort of 30 healthy subjects and associated with normal RV size and function.

Pattern 2 corresponded to a strain-derived curve moving at a steady negative value from peak systolic strain through early diastole, followed by a positive downward shift of the strain-derived curve towards the base line to the end of diastole.

Pattern 3 corresponded to a strain-derived curve moving positively to the base line following peak systolic strain, marked by a slow and steady gradual movement.

Cohen's  $\kappa$  was run to determine if there was agreement between two independent observers for strain-derived diastolic patterns adjudication. There was very good agreement between the two observers' judgements ( $\kappa = 0.64$ , 95% CI, 0.49 to 0.89,  $p=0.0001$ ).

**Table 2.** Clinical, hemodynamic and echocardiographic characteristics of the overall population and the three pattern-groups.


	Pattern-1	Pattern-2	Pattern-3	All
<b>Patients, n</b>	14	26	68	108
<b>Age, years</b>	48±14	58±17	55±14	55±15
<b>Gender, M/F</b>	3/11°	8/18	29/39*	40/68
<b>Weight, Kg</b>	68±20	69±13	71±16	70±16
<b>Height, cm</b>	161±10	163±8	164±8	163±9
<b>WHO, class</b>	2.0±0.2°	2.4±0.5	2.5±0.6*	2.4±0.5
II, n (%)	13 (92.9%) <sup>△</sup> °	14 (53.8%)*	31 (45.6%)*	58 (53.7%)
III, n (%)	1 (7.1%) <sup>△</sup> °	12 (46.2%)*	33 (48.5%)*	46 (42.6%)
IV, n (%)	0 (0%)°	0 (0%)°	4 (5.9%) <sup>△</sup> *	4 (3.7%)
<b>6MWT, m</b>	471±105°	422±52	380±91*	403±83
<b>Hemodynamics</b>				
mPAP, mmHg	33.6±5.6 <sup>△</sup> °	42.6±9.9 <sup>°</sup>	52.5±12.6 <sup>△</sup> *	47.6±13.2
RAP, mmHg	5.5±1.7°	6.0±2.3°	8.8±5.1 <sup>△</sup> *	7.7±4.4
CI, l/min/m <sup>2</sup>	2.8±0.5°	2.6±0.4°	2.3±0.5 <sup>△</sup> *	2.4±0.5
PWP, mmHg	9.5±4.5	10.1±3.4	9.9±4.0	9.9±3.9
PVR, WU	4.8±1.7°	7.4±2.5°	10.1±4.2 <sup>△</sup> *	8.8±4.0
<b>Echocardiography</b>				
RA Area, cm <sup>2</sup>	22.6±2.6°	24.2±4.4°	31.0±10.8 <sup>△</sup> *	28.3±9.6
LV-Eld	1.3±0.1	1.4±0.2	1.5±0.3	1.5±0.2
LV-Els	1.5±0.2	1.7±0.3	1.8±0.4	1.7±0.3
RVEDA, cm <sup>2</sup>	22.3±3.1°	23.5±3.5°	27.7±6.7 <sup>△</sup> *	26.0±6.1
RVESA, cm <sup>2</sup>	12.8±2.2°	14.4±3.5°	17.9±5.9 <sup>△</sup> *	16.4±5.4
RVFAC, %	42.1±6.9°	38.6±8.4	35.9±8.8*	37.3±8.7
TAPSE, mm	21.5±2.9°	20.0±3.2°	17.1±4.1 <sup>△</sup> *	18.3±4.1
Global RV strain, %	-18.7±2.8	-19.5±4.2°	-16.8±4.7 <sup>△</sup>	-17.7±4.5
RV basal 2D strain, %	-23.6±4.9	-19.9±5.6	-17.8±4.7	-19.1±5.3
RV mid 2D strain, %	-22.0±5.0	-19.8±5.9	-18.0±6.0	-19.0±5.9
IVC, mm	16.4±2.2°	16.3±2.1°	19.3±5.0 <sup>△</sup> *	18.1±4.3
Tricuspid regurgitation, n (%)				
mild	13 (92.9%) <sup>°</sup>	17 (65.4%)*	37 (54.4%)*	67 (62%)
moderate	1 (7.1%) <sup>△</sup> °	9 (34.6%)*	28 (41.2%)*	38 (35.2%)
severe	0 (0%)°	0 (0%)°	3 (4.4%) <sup>△</sup> *	3 (2.8%)
Pericardial effusion, n (%)	0 (0%) <sup>△</sup> °	1 (3.8%) <sup>°</sup>	14 (20.6%) <sup>△</sup> *	15 (13.9%)
<b>Therapy</b>				
<i>Baseline</i>				
Diuretics, %	64.3°	73.1°	91.2 <sup>△</sup> *	83.3
Furosemide, mg/die	30.5±16°	32.8±14°	53.2±29 <sup>△</sup> *	46.6±27
Ca-channel blockers, n (%)	2 (14.3) <sup>△</sup> °	2 (7.6)*	3 (4.4)*	7 (6.5)
ERA, n (%)	6 (42.9)°	10 (38.5)°	17 (25.0) <sup>△</sup> *	33 (30.5)
PDE5i, n (%)	4 (28.5)°	8 (30.9)°	12 (17.7) <sup>△</sup> *	24 (22.2)
Epoprostenol i.v., n (%)	0 (0)°	0 (0)°	3 (4.4) <sup>△</sup> *	3 (2.8)
Treprostinil s.c., n (%)	0 (0) <sup>△</sup> °	2 (7.7)*	4 (5.9)*	6 (5.6)
Prostanoid + oral, n (%)	0 (0)°	0 (0)°	14 (20.6) <sup>△</sup> *	14 (13.0)
ERA + PDE5i, n (%)	2 (14.3)	4 (15.3)	15 (22.0)	21 (19.4)
<i>Follow-up</i>				
Diuretics, %	42.9 <sup>△</sup> °	92.3*	97.1*	88.9
Furosemide, mg/die	19.6±24 <sup>△</sup> °	56.0±19*	61.7±32*	54.9±31

LEGEND - *Ca-channel blockers*: calcium channel blockers; *ERA*: endothelin receptor antagonists; *CI*: cardiac index; *IVC*: inferior vena cava; *LV-Eld*: left ventricular end-diastolic eccentricity index; *LV-Els*: left ventricular end-systolic eccentricity index; *mPAP*: mean pulmonary arterial pressure; *PDE5i*: phosphodiesterase-5 inhibitors; *PVR*: pulmonary vascular resistance; *PWP*: mean pulmonary wedge pressure; *RA area*: right atrium area; *RAP*: mean right atrial pressure; *RV*: right ventricular; *RVEDA*: right ventricular end-diastolic area; *RVESA*: right ventricular end-systolic area; *RVFAC*: right ventricular fractional area change; *TAPSE*: tricuspid annular plane systolic excursion; *WHO*: World Health Organization; *6MWT*: 6-minute walking test.

\* p<0.05 vs Pattern 1

△ p<0.05 vs Pattern 2

° p<0.05 vs Pattern 3



**Figure 10.** Right ventricular strain-derived patterns by speckle tracking echocardiography. Panel A. Normal pattern in healthy subjects. Panel B. Pattern 1 in PAH patients. Panel C. Pattern 2 in PAH patients. Panel D. Pattern 3 in PAH patients. LEGEND - PAH: pulmonary arterial hypertension.

### 5.3.2 2D diastolic patterns and RV adaptation to afterload

The clinical, hemodynamic and echocardiographic characteristics associated with the three diastolic strain patterns are shown in Table 2.

Pattern 1 was associated with a low hemodynamic burden as characterized by mild to moderate PH, low RAP and preserved CI. Most of the patients were in WHO class II with mild degree of exercise limitation. These patients were most likely to have mild RV and RA dilation, as well as left ventricular compression, and low rates of severe tricuspid


regurgitation and pericardial effusion. RV systolic function parameters, as expressed by RVFAC, TAPSE and peak systolic strain, were preserved.

Pattern 2 was associated with severe PH but preserved RAP and CI. Half of the patients were in WHO class III with poor exercise capacity. These patients had RV and RA dilation, increased LV compression and low rates of pericardial effusion. This cohort has preserved RV systolic function with similar RVFAC, TAPSE and peak systolic strain as compared to the previous cohort.

Pattern 3 includes the largest number of patients. This pattern was associated with advanced WHO functional class and very poor exercise capacity. Patients had pronounced right heart remodeling showing severe RV and RA dilation associated with LV compression and a high percentage of patients with moderate to severe tricuspid regurgitation and pericardial effusion. Average RV systolic function was reduced as documented by RVFAC, TAPSE and peak systolic strain.


Figure 11 highlights the corresponding RAP curve and IVC size for each strain-derived RV diastolic pattern.

Figure 12 shows how for mild to moderate RV dilation higher PVR are associated with higher degree of diastolic patterns from 1 to 3, while for severe RV dilation diastolic patterns are limited to Pattern 3. Furthermore, it shows the correlation between RVEDA and RVFAC encoded for the diastolic pattern distribution. Visual inspection of the scatterplot shows how all three diastolic patterns are consistent with mild to moderate dilation of the RV together with mild to moderate reduction of systolic function, while severe RV dilation and systolic dysfunction are associated only with Pattern 3.



**Figure 11.** RAP curves and IVC size based on strain-derived RV diastolic patterns. The corresponding RAP curve and IVC size are reported for each pattern.


LEGEND - IVC: inferior vena cava; RAP: right atrial pressure; RV: right ventricular.



**Figure 12.** Correlation between RVEDA, RVFAC and PVR based on strain-derived RV diastolic pattern distribution (Pattern 1, brown squares; Pattern 2, yellow triangles; Pattern 3, grey circles). Panel A. RVEDA versus PVR. Panel B. RVEDA versus RVFAC.

LEGEND - PVR: pulmonary vascular resistance; RV: right ventricular; RVEDA: right ventricular end-diastolic area; RVFAC: right ventricular fractional area change.

Finally, Figure 13 highlights that Patterns 1 and 2 are usually associated with preserved RAP, while Pattern 3 is characterized by high values of RAP. Interestingly, while high RAP corresponds usually to dilated inferior vena cava and a Pattern 3 distribution, Patterns 1 and 2 are associated both with preserved RAP and normal inferior vena cava diameter.



**Figure 13.** Correlation between RVEDA, RAP and IVC size based on strain-derived RV diastolic pattern distribution (Pattern 1, brown squares; Pattern 2, yellow triangles; Pattern 3, grey circles). Panel A. RVEDA versus RAP. Panel B. IVC size versus RAP. LEGEND - IVC: inferior vena cava; RAP: right atrial pressure; RVEDA: right ventricular end-diastolic area.

### 5.3.3 2D diastolic patterns and clinical worsening

The median follow-up time in the cohort was 536 days (IQR 270-732 days) and 55 (50.9%) patients presented with episodes of CW, including 21 deaths (19.4%).

At univariate analysis the following variables resulted predictive of CW: WHO functional class, 6MW distance, RAP, CI, PVR, RA area, LV-EId, LV-EIs, RVEDA, RVESA, RVFAC, TAPSE, basal RV free wall (FW) peak strain, mid-RVFW peak strain, global strain, pericardial effusion, strain-derived diastolic patterns.



Cox regression Model-1 for CW prediction was constructed with those variables significantly resulting from univariate analysis excluding strain-derived diastolic patterns. Six-minute walk distance, RAP and RVEDA emerged as independent predictors of CW (Table 3). Adding strain-derived diastolic patterns, Model-2 was generated, in which only RVEDA and diastolic patterns resulted independent predictors of outcome.

The c-statistic accuracy comparison between the two models demonstrated incremental prognostic power of Model-2 versus Model-1 for CW (area under the curve: 0.78 vs 0.66, respectively;  $p < 0.001$ ).

Risk of clinical worsening for each diastolic pattern-group was estimated with Pattern 1 (lowest risk) as the comparator group. Compared with Pattern 1, risk of CW ranged from 7.0 (C.I. 1.31 to 54.8;  $p = 0.03$ ) for Pattern 2 to 11.2 (C.I. 1.52 to 83.1;  $p = 0.01$ ) for Pattern 3.

Most of the CW events among Pattern 2 patients were related to hospitalization for congestive heart failure (80%), while for Pattern 3 patients both hospitalization and death were equally represented.


The percentage of patients treated with diuretics at baseline and the mean daily dosage was similar in Pattern 1 and Pattern 2, although the latter goes through higher dosage during follow-up with increased patients rate started on diuretics compared with Pattern 1. With regard to Pattern 3, these patients presented higher rates of diuretic therapy with higher daily dosage compared with the other two patterns and underwent higher daily dosage during follow-up.

Based on the Kaplan-Meier curves for percent free from CW (Figure 14), patients with Pattern 1 presented with the lowest rates of CW, while those with Pattern 3 had the highest rates. The freedom from CW rates at 1 and 2 years from baseline were, respectively, 100% and 93% for Pattern 1; 80% and 55% for Pattern 2; 60% and 33% for Pattern 3 (Pattern 1 vs 2,  $p = 0.0001$ ; Pattern 1 vs 3,  $p = 0.0001$ ; Pattern 2 vs 3,  $p = 0.03$ ).

**Table 3.** Cox regression models for clinical worsening prediction: Model-1 and Model-2.

	Unit	HR	(95% CI)	p	C-statistic (95% CI)
<b>Model-1</b>					0.66 (0.55-0.76)
6MWT	1	0.99	(0.991-0.998)	0.001	
RAP	1	1.06	(1.01-1.13)	0.03	
RVEDA	1	1.05	(1.01-1.10)	0.009	
<b>Model-2</b>					0.78 (0.70-0.88)
RVEDA	1	1.06	(1.03-1.11)	0.001	
Diastolic strain					
Pattern 1					
Pattern 2		7.0	(1.31-54.8)	0.03	
Pattern 3		11.2	(1.52-83.1)	0.01	

LEGEND - RAP: mean right atrial pressure; RVEDA: right ventricular end-diastolic area; WHO: World Health Organization; 6MWT: 6-minute walking test.



**Figure 14.** Kaplan-Meier event-free survival curves of the three groups of patients based on strain-derived right ventricular diastolic patterns. Pattern 1 (brown line) patients had significantly a better prognosis compared with the others, followed by Pattern 2 (yellow line) and Pattern 3 (grey line) patients (Pattern 1 vs 2,  $p=0.0001$ ; Pattern 1 vs 3,  $p=0.0001$ ; Pattern 2 vs 3,  $p=0.03$ ).

## 5.4 DISCUSSION

The results of the present study show that RV strain analysis by 2D speckle tracking echocardiography allows to describe three different strain-derived diastolic patterns that are feasible to recognize in the majority of IPAH patients with high reproducibility. This provides for the first time a tool for evaluation of RV real diastolic function, overcoming the limits of previously used methods which prevented routine use in clinical practice, such as invasive and sometimes risky measurements, complex mathematical modeling, RM imaging temporal resolution. Our study also shows that STE evaluation of diastolic function presents a clinical added value, since it allows to individuate those patients at high risk of clinical worsening though presenting preserved RV systolic function and right atrial pressure.

The three patterns are clearly associated with different pathophysiologic conditions characterized by progressive increased RV afterload and chamber remodeling from Pattern 1 to 3.

Pattern 1 resembles diastolic pattern derived from healthy subjects observation. Indeed Pattern 1 patients present mild hemodynamic, clinical and RV remodeling involvement, and normal standard echocardiographic RV systolic function indices.

Pattern 2 allows pathophysiologic speculations that might be explained by changes in the early diastole (isovolumic relaxation and rapid filling). Indeed, the early diastole is mainly characterized by the uptake of  $\text{Ca}^{2+}$  by the sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase (SERCA) pump and a sarcolemma  $\text{Na}^+$ - $\text{Ca}^{2+}$  exchanger (NCX), removing 70% and 28%, respectively, of the cytosolic  $\text{Ca}^{2+}$ . Evidence in the LV suggests that the relative contributions of SERCA and NCX are altered in failing hearts, with a detrimental shift toward NCX, that is energetically more expensive than the SERCA system and decreases the amount of  $\text{Ca}^{2+}$  available for release during systole.<sup>(101)</sup> This agreed with the results of Amsterdam Group's studies on single-beat RV diastolic evaluation, demonstrating increased cardiomyocyte stiffness and myofilament  $\text{Ca}^{2+}$  sensitivity (which is a sign of hypercontractile sarcomeres),

alterations in  $\text{Ca}^{2+}$ -handling proteins and reduced SERCA2a levels in PAH patients, contributing to RV diastolic dysfunction due to insufficient diastolic  $\text{Ca}^{2+}$  clearance.<sup>(5,6)</sup>

Changes in early relaxation physiology (isovolumic relaxation and rapid filling) seem not to exert significant effects on end-diastolic pressure,<sup>(102)</sup> in accordance with our Pattern 2 patients, who present normal right atrial pressure and inferior vena cava diameter and collapsibility.

Pattern 3 allows further pathophysiologic speculations. Indeed, myocardial relaxation is also influenced by the inherent viscoelastic properties of the myocardium. Structural alterations in the contractile elements and in the extracellular matrix may be a source of ventricular remodeling as result of chronic pressure overload and are typically associated with altered ventricular compliance,<sup>(103)</sup> characterized by high end-diastolic pressure, as observed in our Pattern 3 patients. This agrees once again with previous studies that confirmed alterations in the extracellular matrix and cardiomyocyte sarcomeres, contributing to increased diastolic stiffness in PAH.<sup>(5,6)</sup>

On the base of such results, we could hypothesize that RV diastolic impairment in PAH patients has different underlying mechanisms depending on the stage of the disease: Pattern 1 patients, with mild pulmonary hypertension, do not have evident diastolic dysfunction; Pattern 2 patients, affected by mild to moderate PAH with positive adaptive RV remodeling and low RV filling pressures, are characterized by an involvement of the first phase of diastolic relaxation, due to altered molecular mechanisms; Pattern 3 patients, with severe disease associated to maladaptive RV remodeling, may present a main involvement of the last phase of diastolic relaxation, due to more predominant structural alterations. These findings could be supported by the results of a previous study on a large PAH population,<sup>(7)</sup> demonstrating that RV diastolic stiffness is explained by the increased wall thickness in patients with >5 years survival (presenting adaptive RV phenotype with hypertrophy and increased contractility explained by increased  $\text{Ca}^{2+}$ -sensitivity, who may

correspond to our Pattern 2 patients), but not in those surviving <5 years, in which RV stiffness could be predominantly due to stiffening of the RV cardiomyocytes themselves (who may correspond to our Pattern 3 patients with maladaptive RV phenotype), suggesting that intrinsic myocardial changes play a distinctive role in explaining RV diastolic stiffness at different stages of PAH.

Our speculations could also be supported by a subsequent rat model of PAH,<sup>(104)</sup> demonstrating that RV myocardial stiffness is increased in rats with both mild and severe RV dysfunction. While in mild RV dysfunction, stiffness seems mainly determined by increased myofibril stiffness, in severe RV dysfunction, both myofibril- and fibrosis mediated stiffness contribute to increased RV myocardial stiffness (as hypothesized in our Pattern 3).

From a clinical point of view, the main contribution of our study is to show that strain-derived diastolic evaluation seems of additive value in clinical practice, as Pattern 2 is able to predict the combined endpoint of morbi-mortality on top of other clinical, hemodynamic and echo parameters.

As evident from the figures, while Pattern 3 is associated with advanced stage of the disease (maladaptive RV phenotype), characterized by high RAP and dilated IVC (thus of limited added value in clinical practice), Pattern 2 is associated with an earlier stage of the disease, characterized by preserved RAP and RV systolic function, but still at higher risk of CW compared with patient with no evidence of RV diastolic dysfunction.

## **5.5 STUDY LIMITATIONS**

First, the current study was not meant to propose a classification of RV diastolic function in IPAH, as the complexity of diastolic function would require a plethora of RV hemodynamic and imaging information difficult to collect. These results serve to underscore the need for novel imaging phenotyping approach for improving the understanding of RV diastolic function. The second possible technical limitation comes from STE analysis, which requires

a training period and experience to achieve reproducible results. However, as a rare disease, IPAH management is mainly restricted to referral centers where expertise on echocardiographic evaluation is a standard of care.

Finally, our findings should be confirmed in a larger multicenter trial to exclude possible type I error inflation given the multiple screened predictors considering the relatively small number of patients with events.

## **5.6 CONCLUSIONS**

The results of the present study suggest that by using speckle tracking echocardiography we can identify three phenotypically distinct, reproducible and clinically meaningful RV diastolic patterns by strain-derived curves. Each strain-derived diastolic pattern is associated with different clinical presentation, hemodynamic condition and RV adaptation to increased afterload. We have also shown the independent prognostic impact of different diastolic patterns on top of commonly used clinical, hemodynamic and echocardiographic parameters. Moreover, Pattern 2 reveals diastolic dysfunction associated with higher risk of clinical worsening in a group of patients with apparently adaptative RV phenotype, based in current knowledge.

Finally, considering the low temporal resolution of cardiac MR (30-40 ms) compared with echocardiography, the latter evaluation gives us the unique possibility to study all diastolic phases including isovolumic relaxation and rapid filling.

These findings highlight the need of improving the understanding of RV diastolic function to improve clinical decision-making process and provide a feasible tool for routinely RV diastolic evaluation in PAH patients.

## REFERENCES

- 
- ( 1 ) McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. *Circulation* 2006;114(13):1417-31.
  - (2) Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. *J Am Coll Cardiol* 2013;62(25 Suppl):D22-33.
  - (3) Westerhof N, Stergiopoulos N, Noble MIM. Snapshots of Hemodynamics: An aid for clinical research and graduate education. 2nd ed. New York, NY: Springer; 2010.
  - (4) Handoko ML, de Man FS, Allaart CP, Paulus WJ, Westerhof N, Vonk-Noordegraaf A. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. *Eur Respir Rev* 2010;19(115):72-82.
  - (5) Rain S, Handoko ML, Trip P, et al. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. *Circulation* 2013;128(18):2016-25.
  - (6) Rain S, Bos Dda S, Handoko ML, et al. Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertension. *J Am Heart Assoc* 2014;3(3):e000716.
  - (7) Trip P, Rain S, Handoko ML, et al. Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension. *Eur Respir J* 2015;45(6):1603-12.
  - (8) Takeda Y, Sakata Y, Higashimori M, et al. Noninvasive assessment of wall distensibility with the evaluation of diastolic epicardial movement. *J Card Fail* 2009;15(1):68-77.
  - (9) Ohtani T, Mohammed SF, Yamamoto K, et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. *European Heart Journal* 2012;33(14):1742-1749
  - (10) Tello K, Dalmer A, Vanderpool R, et al. Cardiac magnetic resonance imaging-based

---

right ventricular strain analysis for assessment of coupling and diastolic function in pulmonary hypertension. *JACC Cardiovasc Imaging* 2019 Mar 13. pii: S1936-878X(19)30164-0.

(11) Badagliacca R, Poscia R, Pezzuto B, et al. Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: determinants and impact on pump function. *J Heart Lung Transplant* 2015;34(3):381-9.

(12) Badagliacca R, Reali M, Poscia R, et al. Right intraventricular dyssynchrony in idiopathic, heritable, and anorexigen-induced pulmonary arterial hypertension: clinical impact and reversibility. *JACC Cardiovasc Imaging* 2015;8(6):642-652.

(13) Badagliacca R, Papa S, Valli G, et al. Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension. *Eur Respir J* 2017;49(6).

(14) MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part one. *Am J Respir Crit Care Med* 1994;150(3):833-52.

(15) Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the pathophysiology and treatment management of pulmonary hypertension. *Cardiovasc Res* 1999;44(2):274-82.

(16) Zhu L, Wiggle D, Hinek A. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adpsin. *J Clin Invest* 1994;94(3):1163-7.

(17) Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. The prevalence of right and left ventricular dysfunction in patients with severe pulmonary disease. *Chest* 1998;113(3):576-583.

(18) Galiè N, Humbert M, Vachiery J-L, et al. Authors/Task Force Members. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the



---

European Society of Cardiology (ESC) and the European Respiratory Society (ERS)  
Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC),  
International Society for Heart and Lung Transplantation (ISHLT). *European Heart  
Journal* 2016;37(1):67-119.

(19) Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. *Ann Internal Med* 1987;107(2):216-223.

( 20 ) Executive summary from the World Symposium on Primary Pulmonary Hypertension. Rich S. Editor <http://www.who.int/ncd/cvd/pph.html>.

(21) Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019;24;53(1). pii: 1801913.

(22) Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol* 2013;62(25 Suppl):D13-D21.

(23) Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. *Circulation* 2005;112(4):553-62.

(24) Harrison RE, Berger R, Haworth SG, et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. *Circulation* 2005;111(4):435-441.

(25) Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. *N Engl J Med* 2013;369(4):351-361.

(26) Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *Eur Respir J* 2019 Jan 24;53(1). pii: 1801887.

(27) Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. *Eur Respir Rev* 2014;23(134):476-487.

- 
- (28) Naeije R, Brimiouille S, Dewachter C. Biomechanics of the right ventricle. *Pulm Circ*. 2014;4(3):395-406.
- (29) Vonk-Noordegraaf A, Westerhof N. Describing right ventricular function. *Eur Respir J* 2013;41(6):1419-23.
- (30) West JB. Role of the fragility of the pulmonary blood-gas barrier in the evolution of the pulmonary circulation. *Am J Physiol Regul Integr Comp Physiol* 2013;304(3):R171-R176.
- (31) West JB. Ibn al-Nafis, the pulmonary circulation, and the Islamic Golden Age. *J Appl Physio* 2008;105(6):1877-80.
- (32) Haddad SI, Khairallah AA. A forgotten chapter in the history of circulation of the blood. *Ann Surg* 1936;104(1):1-8.
- (33) Young RA. The pulmonary circulation - Before and after Harvey: Part I. *Br Med J* 1940;1(4122):1-5.
- (34) Haddad F, Hunt SA, Rosenthal DN, et al. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation* 2008;117(11):1436-48.
- (35) Starr I, Jeffers WA, Meade RH. The absence of conspicuous increments of venous pressure after severe damage to the right ventricle of the dog, with a discussion of the relation between clinical congestive heart failure and heart disease. *Am Heart J* 1943;26(26):291-301.
- (36) Kagan A. Dynamic responses of the right ventricle following extensive damage by cauterization. *Circulation* 1952;5(6):816-23.
- (37) Fontan F, Baudet F. Surgical repair of tricuspid atresia. *Thorax* 1971;26(3):240-248.
- (38) Gewillig M. The Fontan circulation. *Heart* 2005;91(6):839-846.
- (39) Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure report of a National Heart, Lung, and Blood Institute Working Group on cellular and

---

molecular mechanisms of right heart failure. *Circulation* 2006;114(17):1883-1891.

(40) Naeije R. Assessment of right ventricular function in pulmonary hypertension. *Curr Hypertens Rep* 2015;17(5):35.

(41) Santamore WP, Dell'Italia LJ. Ventricular interdependence: significant left ventricular contributions to right ventricular systolic function. *Prog Cardiovasc Dis* 1998;40(4):289-308.

(42) Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. *Circulation* 2008;117(13):1717-31.

(43) Guyton AC, Lindsey AW, Gilluly JJ. The limits of right ventricular compensation following acute increase in pulmonary circulatory resistance. *Circ Res* 1954;2(4):326-332.

(44) Sagawa K, Maughan L, Suga H, Sunagawa K. *Cardiac Contraction and the Pressure-Volume Relationship*. New York: Oxford University Press, 1988.

(45) Sarnoff SJ, Mitchell JH, Gilmore JP, et al. Homeometric autoregulation of the heart. *Circ Res* 1960;8:1077-1091.

(46) Suga H, Sagawa K, Shoukas AA. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. *Circ Res* 1973;32(3):314-322.

(47) Maughan WL, Shoukas AA, Sagawa K, Weisfeldt ML. Instantaneous pressure-volume relationship of the canine right ventricle. *Circ Res* 1979;44(3):309-315.

(48) Sunagawa K, Yamada A, Senda Y, et al. Estimation of the hydromotive source pressure from ejecting beats of the  $\left[ \begin{array}{c} \text{L} \\ \text{SEP} \end{array} \right]$  left ventricle. *IEEE Trans Biomed Eng* 1980;27(6):299-305.

(49) Brimiouille S, Wauthy P, Ewalenko P, et al. Single-beat estimation of right ventricular end-systolic pressure-volume  $\left[ \begin{array}{c} \text{L} \\ \text{SEP} \end{array} \right]$  relationship. *Am J Physiol Heart Circ Physiol* 58

---

2003;284(5):H1625-H1630.

(50) Badagliacca R, Poscia R, Pezzuto B, et al. Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. *J Heart Lung Transplant* 2015;34(3):395-403.

(51) D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 1991;115(5):343-349.

(52) Bossone E, D'Andrea A, D'Alto M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. *J Am Soc Echocardiogr* 2013;26(1):1-14.

(53) Roberts JD, Forfia PR. Diagnosis and assessment of pulmonary vascular disease by Doppler echocardiography. *Pulm Circ* 2011;1(2):160-181.

(54) Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol* 2002;39(7):1214-9.

(55) Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr* 2009;22(12):1368-74.

(56) Ernande L, Cottin V, Leroux PY, et al. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. *J Am Soc Echocardiogr* 2013;26(3):297-306.

(57) Vonk-Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. *Eur Respir J* 2019;53(1). pii: 1801900.

(58) Tello K, Dalmer A, Vanderpool R, et al. Impaired right ventricular lusitropy is associated with ventilatory inefficiency in PAH. *Eur Respir J*. 2019 Sep 12. pii: 1900342.

(59) Marcus JT, Westerhof BE, Groeneveldt JA, et al. Vena cava backflow and right ventricular stiffness in pulmonary arterial hypertension. *Eur Respir J* 2019;54(4). pii: 59

---

1900625.

(60) Murayama M, Okada K, Kaga S, et al. Simple and noninvasive method to estimate right ventricular operating stiffness based on echocardiographic pulmonary regurgitant velocity and tricuspid annular plane movement measurements during atrial contraction. *Int J Cardiovasc Imaging* 2019;35(10):1871-1880.

(61) Hayabuchi Y, Homma Y, Kagami S. Right ventricular myocardial stiffness and relaxation components by kinematic model-based transtricuspid flow analysis in children and adolescents with pulmonary arterial hypertension. *Ultrasound Med Biol.* 2019 Aug;45(8):1999-2009.

(62) Lazar JM, Flores AR, Grandis DJ, Orié JE, Schulman DS. Effects of chronic right ventricular pressure overload on left ventricular diastolic function. *Am J Cardiol* 1993;72(15):1179-1182.

(63) Belenkie I, Horne SG, Dani R, Smith ER, Tyberg JV. Effects of aortic constriction during experimental acute right ventricular pressure loading: further insights into diastolic and systolic ventricular interaction. *Circulation* 1995;92(3):546-554.

(64) Damiano RJ Jr, La Follette P Jr, Cox JL, et al. Significant left ventricular contribution to right ventricular systolic function. *Am J Physiol* 1991;261(5 Pt 2):H1514-H1524.

(65) Marcus JT, Gan CT, Zwanenburg JJ, et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. *J Am Coll Cardiol* 2008;51(7):750-757.

(66) Vonk Noordegraaf A, Haddad F, Bogaard HJ, Hassoun PM. Noninvasive imaging in the assessment of the cardiopulmonary vascular unit. *Circulation* 2015; 131(10):899-913.

(67) Feigenbaum H. *Echocardiography*. Philadelphia, PA: Lea & Febiger, 1994.

(68) Otto CM. *The practice of clinical echocardiography*. 2nd edition. Philadelphia, PA: 60

---

WB Saunders, 2002:739-60.

(69) Anavekar NS, Gerson D, Skali H, Kwong RY, Yucel EK, Solomon SD. Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study. *Echocardiography* 2007;24(5):452-6.

(70) Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. *Am Heart J* 1984;107(3):526-31.

(71) Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr* 2010;23(7):685-71.

(72) Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol* 2002;39(7):1214-9.

(73) Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med* 2006;174(9):1034-41.

(74) Ghio S, Pazzano AS, Klersy C, et al. Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension. *Am J Cardiol* 2011;107(4):628-32.

(75) Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. *J Am Soc Echocardiogr* 2009;22(12):1368-74.

(76) Ernande L, Cottin V, Leroux PY, et al. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. *J Am Soc Echocardiogr* 2013;26(3):297-306.

(77) Teske AJ, De Boeck BWL, Melman PG, Sieswerda GT, Doevendans PA, Cramer MJM. Echocardiographic quantification of myocardial function using tissue deformation 61

---

imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking. *Cardiovascular Ultrasound* 2007;5:27.

(78) Urheim S, Cauduro S, Frantz R, et al. Relation of tissue displacement and strain to invasively determined right ventricular stroke volume. *Am J Cardiology* 2005;96(8):1173-1178.

(79) Amundsen BH, Helle-Valle T, Edvardsen T, et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. *J Am Coll Cardiol* 2006;47(4):789-793.

(80) Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. *J Am Coll Cardiol* 2012;59(17):1509-18.

(81) Pirat B, McCulloch ML, Zoghbi WA. Evaluation of global and regional right ventricular systolic function in patients with pulmonary hypertension using novel speckle tracking method. *Am J Cardiol* 2006;98(5):699-704.

(82) Cho GY, Chan J, Leano R, Strudwick M, Marwick TH. Comparison of two dimensional speckle and tissue velocity based strain and validation with harmonic phase magnetic resonance imaging. *Am J Cardiol* 2006;97(11):1661-1666.

(83) Ishizu T, Seo Y, Atsumi A, et al. Global and regional right ventricular function assessed by novel three-dimensional Speckle-Tracking echocardiography. *J Am Soc Echocardiogr* 2017;30(12):1203-1213.

(84) Geva T, Powell AJ, Crawford EC, Chung T, Colan SD. Evaluation of regional differences in right ventricular systolic function by acoustic quantification echocardiography and cine magnetic resonance imaging. *Circulation* 1998;98(4):339-345.

(85) Meris A, Faletra F, Conca C, et al. Timing and magnitude of regional right ventricular function: a speckle tracking-derived strain study of normal subjects and patients with right

---

ventricular dysfunction. *J Am Soc Echocardiogr* 2010;23(8):823-31.

(86) Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. *Am J Cardiol* 2006;98(4):530-4.

(87) Fine NM, Chen L, Bastiansen PM, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. *Circ Cardiovasc Imaging* 2013; 6(5):711-721.

(88) Amsallem M, Sweatt AJ, Aymami MC, et al. Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension: comparison with validated models. *Circ Cardiovasc Imaging* 2017;10(6):e005771.

(89) López-Candales A, Dohi K, Bazaz R, Edelman K. Relation of right ventricular free wall mechanical delay to right ventricular dysfunction as determined by tissue Doppler imaging. *Am J Cardiol* 2005;96(4):602-6.

(90) Schwartz DJ, Kop WJ, Park MH, et al. Evidence for early right ventricular and septal mechanical activation (interventricular dyssynchrony) in pulmonary hypertension. *Am J Cardiol* 2008;102(9):1273-1277.

(91) López-Candales A, Rajagopalan N, Dohi K, Edelman K, Gulyasy B. Normal range of mechanical variables in pulmonary hypertension: a tissue Doppler imaging study. *Echocardiography* 2008;25(8):864-872.

(92) Kalogeropoulos AP, Georgiopoulou VV, Howell S, et al. Evaluation of right intraventricular dyssynchrony by two-dimensional strain echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr* 2008;21(9):1028-34.

(93) Pezzuto B, Forton K, Badagliacca R, Motoji Y, Faoro V, Naeije R. Right ventricular dyssynchrony during hypoxic breathing but not during exercise in healthy subjects: a speckle tracking echocardiography study. *Exp Physiol* 2018;103(10):1338-1346.

(94) Lamia B, Muir JF, Molano LC, et al. Altered synchrony of right ventricular contraction 63



---

in borderline pulmonary hypertension. *Int J Cardiovasc Imaging* 2017;33(9):1331-1339.

(95) Choudhury A, Magoon R, Malik V, Kapoor PM, Ramakrishnan S. Studying diastology with speckle tracking echocardiography: The essentials. *Ann Card Anaesth* 2017;20(Supplement):S57-S60.

(96) Magoon R, Malik V, Choudhury A, et al. A Comparison of the strain and tissue Doppler-based indices as echocardiographic correlates of the left ventricular filling pressures. *J Cardiothorac Vasc Anesth* 2018;32(3):1297-1304.

(97) Badagliacca R, Papa S, Valli G, et al. Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension. *Chest* 2016;150(6):1313-1322.

(98) NTNU-Trondheim Norwegian University of Science and Technology Strain rate imaging; [www.ntnu.edu/isb/echocardiography](http://www.ntnu.edu/isb/echocardiography).

(99) DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988;44(3):837-845.

(100) Altman, D. G. 1999. *Practical statistics for medical research*. New York, NY: Chapman & Hall/CRC Press.

(101) Villars PS, Hamlin SK, Shaw AD, Kanusky JT. Role of diastole in left ventricular function, I: Biochemical and biomechanical events. *Am J Crit Care*. 2004 Sep;13(5):394-403

(102) Weisfeldt M, Frederiksen J, Yin F, Weiss J. Evidence of incomplete left ventricular relaxation in the dog. *J Clin Invest* 1978;62(6):1296-1302.

(103) Libby P, Lee R. Matrix matters. *Circulation* 2000;102(16):1874-1876.

(104) Rain S, Andersen S, Najafi A, et al. Right ventricular myocardial stiffness in experimental pulmonary arterial hypertension: relative contribution of fibrosis and myofibril stiffness. *Circ Heart Fail*. 2016 Jul;9(7). pii: e002636.